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 SUMMARY 
 
Diagnosis is the medical act that identifies the signs and the sy mpto ms  o f  
an il lness. I t  is an unavoidable step before the prescription of any medical 
treatment. Over the last decades, the increasing desire of more precise diagnosis ,  
led to the emergence of new tools: the diagnostic products.  
These products are used to identify and monitor the cause of disorde rs t o  
facilitate and specify the diagnosis, and thus, allow an adaptation of t h e m edi c al 
treatment. Diagnostic products can be imaging probes, labels for immuno as say s , 
reagents, contrast agents, or radiopharmaceutical products.  As  a part of 
diagnostic products, companion diagnostics  are specific of a  t r ea tmen t a nd a r e 
mostly used in cancer therapies. They h el p d ete rmi nin g i f  t he p a tie nt w o ul d 
profit  from a medication, depending on his genotype and possible genetic 
mutations. Phenot yping cocktails are diagnostic products that are used in 
phenotyping to obtain additional information, considering the effect o f  e x ter nal  
environmental factors which can also influence the response to a treatment.  
Diagnostic products permit the personalization of medicine , b y a d apti ng  
the medications to the patient,  optimize the treatment, and reduce potential  s id e 
effects. Despite their great benefit , only a few diagnostic products are developed,  
l imiting the possibility to improve diagnosis and therapeutics. In this manuscript,  
we present 2 diagnostic products formulated with nanoparticulate and 
microparticulate material .  The first  formulation consists in “polymersomes 
containing quantum dots (QDs) for cellular imaging”. These p o ly meri c  v es ic les  
have the capacity to encapsulate highly fluorescent probes l i k e Q D s  to  p r ev ent 
the toxic effect of the latter without altering their imaging properties. The second 
diagnostic product is the “CombiCap, a novel drug formulation for the Basel 
phenotyping cocktail”.  This unique formulatio n i s  e qui va len t t o  t he 6  d o sa ge  
6 
forms composing the Basel cocktail  and presents many advantages that facili tate  
its diagnostic use.   
Both formulated products are intended for diagnostic purposes . T h ey  a re 
safe, reliable, specific, customizable, easy t o  f o r mula te a n d e as y t o  u se . T h ey  
bring precise information on the health status of the patie nt i n  o r der t o  g i ve  a  
better diagnosis, to adapt the medical treatment and to monitor the t h era peut ic  
response. The interest for individualized therapies is growing, and therefore, t he  
development of new diagnostic products needs t o  i nc rea se . I n t he f u tu re,  t he 
personalization of diagnosis and therapeutics will  be a common medical practice.  
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1 GENERAL INTRODUCTION
10 
1.1 Definitions and origins 
1.1.1 Diagnosis 
Diagnosis is defined as the identification  o f  t he n a ture  o f  a n i l ln ess  o r  
other problem by examination of the symptoms. The word d iagnosis derives from 
the ancient Greek διάγνωσις . I t is composed by the p r ef ix  δ ια -  ( di a-)  m ea nin g 
“through” and γνῶσις  (gnosis) meaning “kn owledge” (1). L iterally ,  d i ag no si s i s  
related to the ability to get the knowledge through the observation of symptoms.  
Every medical treatment results from the diagnosis of  a disease or a 
special health condition . Most diagnoses are made on a daily basis in the doctor’s 
office in the case of minor sicknesses such as a cold, a migraine, a stomach f l u o r  
a depression. These common diagnoses consist in identifying a disease, ba sed o n  
the observation of physical and mental symptoms; and paying heed to the 
medical history of the patient (2).  However, some diseases req uire more 
thorough examinations  in order to be diagnosed. To evaluate precisely the health 
condition of a patient,  it  is possible to rely on in vivo  or in vitro  diagnostic 
methods. On the one hand, in vivo  diagnosis is made directly on the p a tie nt a nd  
often relays on medical imaging such as X -rays, computerized tomography  ( C T) ,  
medical resonance imaging (MRI), ultrasounds, or nuclear ma gne tic  r es o na nc e 
(NMR).  On the other hand, in vitro diagnosis consists on the examination of b o dy  
fluids, cells, t issues, or organs taken ahead from the patient’s body.  
1.1.2 Diagnostic  products 
Both types of diagnosis require the use of diagnostic products . T h e l a tte r 
are defined by the FDA as reagents, instruments and systems i ntended to be used 
in the diagnosis of an illness or other health condition to cure, t rea t o r  p re ven t 
diseases (3).  In other words, diagnostic products help physicians in the 
observation and interpretation of a patient’s clinical status, and allow identifying 
and measuring normal or abnormal constituents of body fluids or tissues. In vitro 
diagnostic products are usually reagents (e.g. chemical,  biological or radioac ti ve  
substances),  and are “ intended for use in the collection,  preparation and 
examination of specimens taken from the human body”  (3). The main advantage o f  
in vitro  diagnostic tests is the possibility to analyze the samples after their 
11 
collection, without requiring the presence  o f  t he  p ati ent .  M e anw hil e,  i n  v ivo  
diagnostic tests are done in situ by analyzing a physic al  f ea ture  o f  t he  p ati ent  
with electromedical or imaging instruments. Most in vivo  diagnostic products are 
contrast agents that are used in medical imaging to enhance the visuali za tio n  o f  
fluids or structures such as organs or tumors.  
Since a few times, d iagnostic products are increasingly  d ev elo pe d. T h ey  
are used to obtain more accurate diagnosis and to further prescribe t r eat ment s 
adapted to the patients, in the view of a personalization of the therapies .  
1.1.3 Brief  history of  diagnosis 
In the early years of civilization , the first  healers observed clinical 
symptoms to make diagnoses before recommending any kind of treatments . T h e 
first  written trace of diagnosis was discov er ed b y E d wi n S mi th  o n  a  p apy ru s 
dated from circa 1600 B.C.  I t  compiled older papyruses on surgery;  giving 
anatomical observations, the diagnostic method of 48 health i n juri es  a nd t he ir 
possible treatments (4). Many years later, around 3 0 0 B .C. ,  H ip po c rate s,  a ls o  
known as the “Father of Medicine”, diagnosed diabetes mellitus for the first  t ime 
by tasting the sweetness of patient’s urine when coupled with  o th er s y mpt o ms 
l ike polyuria, polydipsia and p olyphagia (5). During the m i ddl e a ge  i n E ur o pe,  
Christianism rejected any type of science or medi ci ne.  T he  “ w ater  c as ti ng” ,  a  
technique for urine analysis was the only authorized diagnostic method (6). From 
1300, uroscopy became the most commonly performed t es t t o  d ete ct d i se as es 
and abnormal health conditions from the observation of the colo r,  c o ns is ten cy , 
smell  and even taste of the urine. A colorimetric wheel ( Figure 1) was created  t o  
help the physicians making their diagnosis (7).  Uroscopy is a diagnostic  m eth o d 
that was used over centuries. This method can be considered as the starting point 
of modern laboratory diagnosis , and is still  used in the early detection of urinar y 
tract infections, kidneys disorders, l iver problems, diabetes or o t her  me tabo l ic  
conditions and pregnancy (8).   
12 
 
Fi gu re  1 :  Uri nary w he el  from ci rca 1 50 0.  
P h ysi ci an s w ere re fe rri ng to th i s orga nol epti c w he el to ma ke  th e i r d i agnosis ba se d on  th e  p a t i e n t ’ s  u r i n e  
ta ste  a n d  col or.  
The Renaissance brought a new vision on sciences and particularly in 
medicine with the emergence of body dissection to learn about human a nat o my.  
During the following centuries, the invention of several medical instruments such 
as microscope, thermometer, stethoscope, ophthalmoscope,  a nd  l ar yn go sc o pe , 
expended the precision of medical diagnosis .  Chemical and bacteriological 
laboratory tests were also developed to diagnose diseases such as tube rc ulo s is ,  
cholera, typhoid and diphtheria (6).  In the early 20th  century, J.C. Todd published  
the first  edition of the manual entitled “Clinical diagnosis by laboratory 
methods”, to give a description of laboratory diagnosis techniques . T h i s m anu al 
was completed by J.  Henry and has remained a reference book over the years. The 
23 r d  edition is scheduled in 2017 (9). From the 20 t h  c e ntur y,  h uge  p ro gre ss es  
were made in the field of diagnosis; many imaging techniques w er e d is c o ver ed 
such as fluorescence microscopy, X -ray spectroscopy, mass spectrometry, 
electron microscopy. New diagnostic methods were invented like radio-
immunoassays and immune-electrophoresis (10). Diagnostic products were  a lso  
developed to enhance the results of diagnostic procedures, for instance, contra st  
agents, radiolabels, lateral flow assays, and medications for diagno st ic  p ur po s e 
(11). For some time now, the field of medical diagnosis has experienced extensive 
development with the emergence of personaliz ed m ed ic in e, t o  i mp ro ve  e arl y 
diagnosis and to adapt treatments to each patient  ( 1 2) .  T hi s p r oj ec t  r eq uire s 
advanced technologies and products to give the possibility to make precise 
13 
diagnosis and deliver the accurate drug to the righ t p ers o n,  a t  t he r i ght  t ime,  
with the appropriate pharmaceutical form, with the correct dose and with a good 
quality.  For this purpose, the application of particulate material such as 
nanoparticles and microparticles is a great  benefit.  
1.2 Nanoparticles for imaging and diagnostics 
Nanotechnology applied to molecular diagnosis is known as 
nanodiagnostics (13). With the increase of interest in the field of 
nanotechnologies, several nanoparticles were developed for a diagnosis purpose. 
These nanodiagnostics products have 2 main functions; the first  one  a s i m agi ng 
agents to enhance visualization of body tissues (14) and the second one as label s 
for diagnostic immunoassays (15) .  Even potenti al  d i agn o sti c  a ppli c ati o ns o f  
nanoparticles are very broad, current applicati o ns a r e o n ly  d ev elo p ed i n  th e 
fields of medical imaging, biomarker research, cancer diagnosis and detect io n o f  
infectious diseases (16).  
1.2.1 Medical molecular imaging 
For the past 40 years, the evolution of molecular i ma gi ng h as  i mpr o ve d 
the early detection of diseases (17). Medical imaging consists in the non-invasive 
evaluation of anatomical and functional characteri sti c s t o  f a ci li tat e t he e a rly  
diagnosis, identify the stage of disease, provide  i nf o rma tio n o n  p hy s io lo g ic al 
abnormalities and can help in following the efficacy of a medical treatment ( 1 8) .  
The most common imaging procedures for clinical diagnosis are MRI  and 
ultrasounds to get information about soft t issues . Computer  t o mo gra phy  g iv es  
information about structures and particularly bones . Positron emission 
tomography (PET) and single photo emission computer tomography (SPECT) a re  
used to obtain information about metabolic paramete rs . O p tic al  i mag ing  i s a s  
well  a common procedure used to get precise images of soft  t issues (17,19).  
For a better visualization and characteriz a tio n  o f  b io lo g ic al  p ro ce ss es  
during molecular imaging, it is recommended to use sensitive molecular imagi ng  
probes (13). Nanoparticles are well  described in the literature for imaging 
purposes. There is a variety of nanoprobes such as polymeric particles and 
vesicles, l iposomes, superparamagnetic iron oxide nanoparticles  ( S PIO Ns) ,  a nd 
metallic nanoparticles i .e. ytterbium, bismuth, and gold nan o par tic le s ( 1 9, 20) . 
14 
Generally,  nanoparticles for diagnosis range between 5 -100 nm and are 
combined with low molecular weight contrast agents to optimize their 
pharmacokinetic properties, biodistribution and tissue penetration (14). As t he y 
are not therapeutics, diagnostic products should not i n duc e a ny  p hy si ol o gi ca l 
effect; have a short circulation time, a fast biodegradation and elimination as well 
as a low toxicity (19,21). However, to reach the structure that needs to b e 
visualized, the imaging nanoparticles can be labeled with targeting ligands ( 1 8) .  
Unlike for therapeutics, nanoparticles for diagnostic are not well  develo pe d a nd 
only few are commercialized and used in clinical imaging (22).  
1.2.2 Examples of  nanoparticles for imaging 
1.2.2.1 Superparamagnetic iron oxide nanoparticles (SPIONs) 
SPIONs find their application in MRI and are considered as highly effective 
contrast agent to monitor anatomical,  p hy si ol o gi ca l ,  a n d m o lec ul ar c h ang es  
during the evolution of a disease or a treatme nt.  T he  s upe rpa rama gne tis m i s  
given by their reduced size that is  below a single magnetic domain (23) . S P IO Ns 
present several advantages as compared to traditional contrast agents. They have 
a stronger magnetic signal strength, their toxicity is relatively low, their contrast 
enhancement last longer, their sensitivity is increased, a n d t hey  d o  n ot  r et a in 
their magnetization after the removal of the external magnetic field (14,24).  
SPIONs are commonly used as a core material for passive and active 
targeting. They can be coated with biocompatible polymers such as polyethylen e 
glycol,  dextran, alginate, or other syn thetic polymers. For active targeting, 
l igands like proteins, peptides, nucleosides, or antibodies can be attached  t o t h e 
magnetic iron oxide core via an anchor arm. The advantage of the targeting is the 
accumulation of the SPIONs in the defined cells,  mostly cancer cells.  This 
accumulation permits a better differentiation between tumors and healthy 
tissues on the MRI pictures (25). Only passive-targeting SPIONs are currently  o n  
the market , e.g. Ferristene (Abdoscan®, GE Healthcare, UK) that is used per  o r al 
for gastrosintestinal MRI  (26), and Ferrixan (Resovist®, Bayer Schering, 
Germany) for liver and spleen imaging (27) o r  a t  di f fe ren t p ha ses  o f  c l in ic al  
trials.  Actively targeted SPIONs for tumor cells imaging by MRI  are stil l  on 
development. For instance, Fu at al.  developed an anti-IL-1β monoclonal antibody 
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functionalized SPIONs for the diag nosis and the treatment of acute temporal lobe 
epilepsy (28). Wan et al . worked  on active targeting of the lung adenocar ci no ma 
cells.  They coated SPIONs with oleic acid and car boxymethyl d e xtra n a nd  t hen,  
functionalized them with anti-CD44v6 monoclonal antibody (29).   
 
Fi gu re  2 :  Strate gy of  p a ssive or a cti ve  ta rgetin g of  SP ION s. 
Iron  ox i d e  core  ca n  be  coa te d w i th bi ocom pa tibl e p olymer a n d l a bel ed w i th l i ga nds to a sse ss th e  ta r ge t i n g  
of  ce l l s or tu mors.  Ad a p ted  from Rose n e t a l  ( 24)   
 
1.2.2.2 Quantum dots  
Quantum dots (QDs) are fluorescent nanopar tic le s w i th h i gher  o p tic al  
properties compared to organic dyes. Most of the QDs are made of semiconductor 
materials, usually cadmium (C d) associated with sulfur (CdS), selenium (CdSe) or 
tellurium (CdTe). The size of these nanocrystals is in the range of 2 -10 nm range. 
The wavelength of fluorescence emissio n ( 4 50 nm -  8 50n m) i s  r el ate d t o  t he 
dimension of the QD, allowing all  colors for imaging and diagnostic assay s.  M ai n 
advantages of QDs are a long fluorescence lifetime and an impe rc epti ble  p ho to  
bleaching over hours (30).  
QDs are generally used as fluorophores in diagnostic optic al i m agi ng f o r  
cancer applications, including the cellular and molecular imaging of tumors. Thi s 
imaging method has a good sensitivity and i s  n on -in va si ve,   b u t s uc h o p ti ca l 
technique is l imited in term of t issue penetration depth  (31). In order to increase 
the residence time of the QDs in the body, a polymeric coating can be appl ied  o n  
their surface and it is possible to target a defined cell l ine after conjugation w it h 
bioactive molecul es. For instance, Akerman e t  a l .  l a bel ed Q D s  w ith d i f fe ren t 
peptides specific to vascular sites:  one peptide bonded cells in lung blood 
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vessels; the other bounded to lymphatic vessels and tumor cell s.   E a ch  p epti de  
targeted the dedicated site in mice, show ing that the QDs can be targeted i n  v i vo  
with a good specificity (32). However, the use of QDs is l imited by the toxici ty  o f  
their  heavy-metal core (33). I t is essential  to prevent this toxic effect f o r  i n  v i vo  
imaging and diagnostic use. In chapter 3, the article “Polymerso mes  c o nta ini ng  
quantum dots for cellular imaging” describes a method for iso lat ing  t he Q D s  i n 
polymeric nanovesicles called polymersomes, while  p res er vi ng t he ir i m agi ng  
properties. The polymer shell could protect the cells from death without alterin g 
the fluorescent optical features of the QDs (34).  
1.2.2.3 Gold nanoparticles  
Gold nanoparticles are  largely used in multiple imaging procedures 
because they present many benefits.  They are easy to synthetize w it h a  p rec i se 
control of the particle size and shape. They have a low sh o rt t er m t o xic i ty a n d 
can be tuned by surface modification or bio-conjugat io n  ( 14 ) . T h e u se  o f  g o ld  
nanoparticles for computer tomography was established 10 years ago , by 
Hainfeld et  al .  to detect breast tumors in mice. They showed that gold 
nanoparticles can be used as contrast agents with properties that ov e rc o me  t he  
limitations of iodine-based agents. Few minutes after i nj ec tio n , t he y o b tai ne d 
high-resolution pictures of the tumor, kidneys, and blood vessels  (Figure  3 ) .  N o  
toxic effect was detected after renal excretion, indicating the s afety of gold 
nanoparticles as a contrast agent (35). The contrast of pictures a n d t he t i me o f  
circulation in the blood can be extended by a pegylated coating of the gold 
nanoparticles (36,37).  
 
Fi gu re  3 :  X -ra y p icture  of  mou se ki dn eys. 
1 h  a fte r IV i n j ecti on of  gol d n a noparti cles ( a )  a nd con ven tiona l i odi ne con t ra st a gent ( b) .   
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Th e  a rrow  sh ow s th e  u rete r ( 1 00 µm d i a mete r).  The  ba r re pre se nts 1  mm. Sou rce H a i nfe ld e t a l .  ( 3 5).  
1.2.2.4 Lipid nanoparticles 
Liposomes have mostly been developed for drug delivery; however, a  f e w 
formulations were developed for diagnosis. In  t he 1 980 s,  t he  f i rs t  l i po so ma l 
radiotracer VesCan® (Vestar Inc. , USA) was developed for in v i vo  i ma gin g.  T he  
liposomes were loaded with the radionucleotide 1 1 1In and were used as 
diagnostic agents for scintigraphy of tumors in clinical trials (38,39). Despite the  
broad development of l iposomes in drug delivery, few researches are focused o n  
liposomes for the diagnostic purpose. Most diagnostic l iposomes are labeled with 
radionucleotides such as 6 7Ga, 1 1 1In, 9 9 mTc, and 1 8F for PET and SPECT imagi ng i n  
the diagnosis of tumors(40–43).  
1.2.3 Nanoparticles as labels in immunoassays: lateral-f low assays  
A lateral-flow assay (LFA) (also called immunodipsticks )  i s a  d i agn o sti c  
tool intended to reveal the presence or the absence of a compoun d i nd ic ati ng a  
health condition like a pregnancy (44,45), a metabolic disorder such as 
cardiovascular disease (46–48), a kidney failure (49,50) , o r  d ia bete s ( 5 1– 53) .  
These LFAs can also be used to detect pathogenic infections (54–60), bio-warfare 
agents (61,62), toxins in food or water (63–68) as well as the presenc e o f  d r ugs  
of abuse in body fluids(69,70). The first  immunodipstick was describe d i n 1 98 6 
by Pappas as an improvement of a dot -ELISA assay  for the diagnosis of 
echinococcosis (71).  
The LFA consists of a strip containing a sample  pa d, a  c o n ju gat e p ad,  a  
detection zone and an  absorption pad (Figure 4)(72). At one extremity, t he 
sample pad permits the inlet  of the sample  on the strip , the conjugate pad 
contains the reactive agents (antibodies) labeled with detection molecules 
(colored nanoparticles). The detection zone has 2 lines, one for the validatio n  o f  
the test (T) and the other to control (C) the functionality of the test ( 7 3) . A t t he  
other extremity, t he absorption pad c a ptu res  t he e xc e ss  o f  s am ple.  T h e L FA 
combines the principle of chromatography and im muno lo g y ( 7 4) .  In dee d, t he  
antigens contained in the liquid sample (blood, urine, tear s,  o r s a li va ) (7 5)  a re 
carried by capillarity to the conjugate pad where they bind to specific antibodi es  
labeled with nanoparticles. The complex analyte-antibody-nanopar tic le  i s t he n 
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recognized by the antibodies that are immobilized at the test l ine. The remaining  
labeled antibodies bind to the immobilized antibodies at the con tro l  l ine . U p o n 
the antigen binding, the nanoparticles aggregate alo ng  t he l i ne a n d p ro duc e a  
visible signal (76). I f the test is positive, 2 colored lines a ris e o n  t he  d ete ct io n 
zone, however, in the case of a negative resul t ,  o n l y t he  c o nt ro l l i ne a p pear s 
because no antigen could bind the antibodies from the test l ine (15).  
The labels are colored or fluorescent nanoparticles.  The visible color 
comes from the immune reaction at  the test  or control l ine (76). These 
nanoparticulate labels are smaller than the pore size of the membran e t o  a vo i d 
any obstruction, and are generally gold nanoparticles ( 7 7– 81) , l a tex  p art ic les  
(82), carbon nanoparticles (83,84), quantum dots (85,86) or liposo mes  ( 6 3,8 7–
89).  
 
Fi gu re  4 :  Sche ma of  a  l a te ral  f l ow  a ssa y 
( a ) .  Sta rt of  a ssa y by a d d ing l i quid sa mp le  ( b).  An tibod ies l a be le d w ith c o l o r e d  n a n o p a r t i c l e s  b i n d  t h e  
a n ti ge n  from th e  sa mp l e  to form a  comp l e x  ( c) .  C omp l e x e s ( a n ti ge n -a n ti bod y-n a n op a rti cl e )  move  by 
ca p i l l arity on  th e  d ete ction p a d a nd  bi nd to te st l i n e  ( positi ve  re sult) ,  l abe le d a nti bodie s w ith out a n t i ge n s  
bi n d  to con trol  l i ne  ( d) .  Sche ma a d apt e d from Ma rk e t a l  ( 72)   
Lateral flow assays are widely developed as diagnostic  p ro du ct s  b ec au se 
they offer many advantages. They are easy to use and do not need sop his ti ca ted  
machines for the interpretation of the results,  m ea nin g t he y c a n b e u s ed a t  a  
point-of-care (e.g. in the doctor’s office, at  home or even in a r e mot e a re a f r o m 
Amazonia).  The time needed to give a diagnosis with a LFA is short b ec au se  t he 
result of the test is visible within 3 to 20 minutes(65). The c o s t o f  d i ag no si s i s  
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also reduced because LFAs are relatively inexpensive (less than 1€ for the 
cheapest) compared to the analyses performed at the hospital or in a laborato ry.  
A small sample (few microliters) is enough to perform the test.  
However, this small  sample size can l ea d t o  a  r edu ce d s en si tiv it y a nd  
specificity that m akes the test more difficult  to interpret.  An o ther  w eak ne ss  o f  
LFAs is the qualitative or semi-quantitative as pec t o f  t h e r e sul t .  I nd eed , i t  i s  
difficult  to quantify a response based on a visual observation. Nonetheless, 
researches are improving the sensit ivity of LFA s with new labels such as 
superparamagnetic nanoparticles (74), indig o  p rec urs o r n an o par tic le s ( 9 0) ,  
platinum nanoparticles (91), modified gold nanoparticles (64,92–94). The 
principle of the LFA itself can also be improved b y  e lec tr oc he mic al  de tec ti o n 
(95,96), magnetic detection (97), Raman scattering ( 9 8)  o r  t he rmal  d ete cti o n 
(99).  
1.3 Microparticles for diagnostic products 
The world health organization (WHO) has defined the Anatomical 
Therapeutic Chemical (ATC) classification system, to provide a standardized to o l 
for drug research and to improve the use  o f  d ru gs . I n t hi s A T C c l as si fi c ati o n 
system, the substances are divided into different groups according t o  t he o r g an 
or system on which they act , and their therapeutic,  pharmacol ogical and chemical 
properties. There is also a category regrouping the diagnostic ag ent s ( c a teg o ry  
ATC V04), the contrast media (category ATC V08) and the diagnostic 
radiopharmaceuticals (category ATC V09) whose use  i s i n ten ded i n  d iag no s is  
purposes (100). From a research point of view, diagnostic microparticles are lef t  
aside, and only few products are available on the market.  Among them, a 
minority is formulated as solid microparticulate product s that are intended to be  
administered by oral,  rectal ,  or venous pathway, or  by inhalation.  The 
manufacturing process of these marketed products i s  e it her n o t  pu bli she d o r  
protected by patents, thus only a  brief description can be given. 
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1.3.1 Category ATC V04: diagnostic  agents  
1.3.1.1 Breath test  for the detection of Helicobacter  pylori 
H. pylori  is a bacteria that is responsible of gastric diseases and can 
increase the risk of developing gastric cancer (101) and can be easily detected by 
a urea breath test .  The difference between the products comes from the 
formulation:  a powder for drinkable solutio n (Helikit ™ ,  Isotechnika Inc, 
Canada)(102), a soluble tablet (Pylobactell®, Torbet Laboratori es , U K ) ( 1 03) , a  
capsule (Helifinder® InBioNet Pharmaceutical)(104) or a tablet (UBiT®, O ts uk a 
Pharmaceuticals, Japan)(105) (106). The patient  ha s t o  i n ges t t he  di ag no st ic  
product, 1 3C labeled urea.  After few minutes, the p a tie nt e x hale s i n  a  t ube t o  
analyze the breath (107).  The bacterial urease coming from H. pylori  hydrolys es  
the urea into ammon ium and bicarbonate, the latter contains the 1 3C isotope th at 
is expired into CO2 , and  can further be measured by mass spectrometry ( 10 8)  o r  
infrared spectrometer (109). The main advantage of this  t es t  i s  t hat i t  i s n o n -
invasive, non-radioactive and can be used on children (102).  
1.3.1.2 Mannitol bronchial challenge test  
A new bronchial test known as Osmohale® (P h arma xis ,  A us tra li a)  w as  
launched in 2010 onto the market as a mannitol challenge test to identify 
bronchial hyper-responsiveness (110). This test enables the diagnosis of as thma  
by measuring the lung function to detect any inflammation of the airways ( 1 11 ) . 
The diagnostic product consists of a capsule of mannitol dry powder that is u se d 
with an inhalation delivery device (112–114). Mannitol is spray dried and mille d 
to obtain particle sizes in the breathable  range (<7µm). The dry po wd er i s  t hen  
encapsulated in hard gelatin capsules with different doses (10, 20 and 40mg) f o r 
cumulative dosage (115).  
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Fi gu re  5 :  O smoh ale ® i nh ala tion  p ow de r i n  h ard ca p sule  for ma nni tol bron chi al ch a ll enge te st.   
D i f fe re nt d oses a re  a vai la ble  i n a  bl i ster w a ll et for cu mul ati ve  d osage ( 1 16).  
1.3.2 Category ATC V08: diagnostic  contrast media 
An important  part of diagnostic products  is intended to enhance the 
visibility of internal body structures and flui ds  du rin g i ma gi ng.  T he  c o nt ras t 
agents are divided in 4 categories: Iodinated and non-iodinated media for X -r ay,  
MRI  contrast media and ultrasound contrast media (117).  
1.3.2.1 Diagnostic products for X-rays 
X-ray contrast products are typically iodine o r  ba ri um c o mpo u nds . F o r 
instance, barium sulfate commercialized under the  br and  n ame M i c ro pa que ® 
(Guerbet, France) is an X-ray contrast media used t o  e xp lo re  t he c o n dit io n o f  
esophagus, stomach, and intestines to diagnose digestive problems. I t  is 
formulated as a barium sulfate suspension and is used for oral or rectal 
administration (118).  
1.3.2.2 Diagnostic products for MRI 
Products for MRI must have magnetic propert ie s t o  b e d et ec ted b y  t he 
scanner. For instance, ferumoxsil is contrast agent commercialized as Lumirem® 
(Guerbet, France). I t is formulated as a suspension of iron oxide cryst als  c o at ed 
with siloxane, that are arranged in a crystalline structure to provide the 
superparamagnetic properties that are compulsory i n  ma gn eti c i ma gi ng ( 2 3) .  
This product is administered orally or rectally for the exploration of the digestive 
tract (119). 
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1.3.2.3 Diagnostic products for ultrasounds 
Echovist® is a contrast medium that was dev elo p ed b y  Ba ye r S c heri ng  
Pharma (Berlin, Germany) for ultrasound examinations.  The echographic 
contrast is obtained by the dispersion of air microbubbles in the blood (120). The 
production of these microbubbles is due to the property of sugars to retain air i n  
their  crystalline network and absorb water on their surface. Echovist ® c o n si sts  
of galactose granules, made of micro-particles whom size is at 9 9% under 12 µm.  
When extemporaneously suspended in appropriate medium and vigorously 
shaken, the  granules break down  into g a lac to s e m ic ro pa rti cl es ,  c a us ing  t he 
production of air microbubbles between the microparticles (121). After injection, 
the galactose microparticles are dissolved and release the  microbubbles, 
inducing an increase of the echo signals from the venous vascular system and the 
observation of the blood flow. The reproducible size of the microbubbles is 
l inked to the granulation process of the galactose but is mainly due to the 
dispersion of the granules into microparticles (122). 
 
Fi gu re  6 :  Sche mati c re prese ntati on of  E ch ovi st® re constituti on from ga la ctose gra nul es.  
Sou rce :  i me dika men t.de   
1.3.3 Category ATC V09: diagnostic  radiopharmaceuticals 
Radiopharmaceuticals are diagnostic products containing  r adi o is ot o pes  
and are used to help in the visualization of internal body struc ture s b y  n uc lea r 
imaging (123). The radioactive compound is g i v en i n  a  v ery  s ma ll  a mo un t b y 
injection, per os,  or by inhalation. The product is designed to be distri bute d i n a  
defined part of the body where the disease or abnormality is lo c ate d a nd  e mits  
radiations that are detected by a γ -camera or by positron emission t o mo gr aphy  
to diagnose patient’s troubles (124). 
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As an example, the Schilling test is performed in 4 s t eps  t o  de ter min e a n 
abnormal absorption of vitamin B12 indicated by low levels.  The patient receives 
a shot of non-radioactive vitamin B12 and swallows  a tablet of 5 7Co-radiolabele d 
vitamin B12 (cyanocobalamin). The urine is  collected during the next 24 hours to 
analyze its radioactivity counts. This test enables t he  d iag no s is  o f  p ern ic io u s 
anemia, that is a consequ ence of a decrease in red blood cells due to a poor 
absorption of vitamin B12 in the intestines (125,126).  
1.4 A step towards personalized medicine  
1.4.1 Current situation 
Given the small  number  of diagnostic products  on the market ;  most 
treatments are prescribed after a simple diagn o sti c  f ro m t he  d o ct o r, a n d a re 
supposed to be based on the sex, age, and weight of the patient.  Medicat io ns  a re 
produced by pharmaceutical industries to fit the largest population and thus, are  
dosed for an adult  of approximately 70 kg (127). However, having the same 
disease does not mean everyone needs the same medication or the same dose.  
F igure 7 illustrates 4 patients with the same disease who were prescribed  
the same treatment, 1 tablet of drug X. The first  patient is a young man, 
approximately 7 0 kg in good physical condition; the treatment is adapted to him.  
The second patient is an old woman, about 45 kg with difficulties to swallow a n d 
a slowed metabolism, the treatment is too strong for her, and not app ro pri ate d, 
she might develop side or even toxic effects. The third patient is  a n o v e rwe igh t 
person; a single tablet may be too low dose and give an incomplete  t hera peu tic  
effect .  The fourth patient is an Asian woman in good physical conditio n , b ut t h e 
medication might not be appropriate or toxic for her because she comes fro m a n  
ethnic group that is not able to metabolize this drug due to of a lack of enzyme.  
This simple example shows that only considering  s ex,  a ge,  w ei ght  f o r a  
prescription is not sufficient,  and conventional prescrip tio n s w it h f i xe d  d os es  
market forms can lead to a lot of low/no-therapeutic effects, overdoses, and s id e 
effects. Indeed, after a systematic review, Kongkaew et al . showed t ha t 5 .3 %  o f  
hospital admissions are associated to drug adverse effects (128). To  l i mi t  t hes e 
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inaccuracies and optimize drug therapie s , i t  i s i mp o rtan t t o  p ers o na liz e  th e 
diagnosis and the treatments to the patient.   
 
Fi gu re  7 :  Il lustrati on of  p e rson ali ze d me di c ine  d epe ndi ng on  e a ch p a tie nt.   
For th e  sa me  d i se ase , th e  sta nda rd tre atme nt d oe s n ot f i t to e ve ry p a tie nt. D e pe ndin g on  th e  p hen ot y p e  o f  
th e  p a ti e nt,  th e tre a tme nt ca n be  a d a pted . It ca n  a l so be  tox i c or i n e ffecti ve be ca use  of  th e  i nad equa te d ose ,  
bu t ca n  a l so be  i n a p propria te be ca use  th e p a tie nt d oes n ot re spon d to th e  mol ecu le .  
1.4.2 Companion diagnostics 
In order to determine if a patient would benefit or not f r o m a  p art ic ula r 
treatment, specific tests known as companion diagnostics were developed (129) .  
According to the FDA, a companion diagnostic refers to an in vitro  or in vivo  
diagnostic tool,  which helps physicians to get the necessary information 
concerning the safe and effective use of a specific drug (130).  
With the companion diagnostics, it is possible to identify the patients who  
can benefit  from a distinct therapeutic treatment, those who have risk to develo p 
serious side effects because of the treatment and to monitor the respons e t o  t he 
treatment to adjust it and improve its safety and it s e f f ic ie nc y.  R ega rdi ng t he  
result of the test, the physician can deci de t o  p re sc ri be o r  n o t p re sc ri be t he  
treatment to the patient (130). For instance, if a patient presents  a  m utat io n i n  
the KRAS gene (involved in the synthesis of the protein K-Ras f o r r e gul ati o n o f  
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the cell division), the action of the target drugs (cetuximab or panit umumab ) i n  
the colorectal tumor tissue would be ineffective to treat the cancer  (131).  
There are 5 types of companion diagnostics: the on es  f o r s c r eeni ng  a nd 
detection to test familial  genetic patterns,  t he p ro g no s is  te st s t o  p re dic t  t he  
future course of a disease, the thera (g)nostic1 companions to verify the patie nt ’ s  
response to the therapy, the monitoring tests to evaluate the e f f ec tiv en ess  a nd  
appropriate dosing of a prescribed therapy and finally the recurrence companion 
diagnostics to analyze the risk of recurrence of the disease (133).  
The rising of companion diagnostic s started in 1998 with the appr o val  o f  
HecepTest™, an immunohistochemistry assay dete ct ing  t he e xp res si o n o f  t h e 
HER2 receptor involved in the growth of cancer cells and thus, dete rmi nin g t he 
efficacy of trastuzumab (Herceptin®, Genentech, USA) f o r  p ati ent s w i th H ER 2 
posit ive breast cancers (134). Since the app ro va l o f  H e rec pT es t™, m a ny n e w 
companion diagnostics devices were developed together  w ith  t arg ete d c an ce r 
drugs to bring effective a nd safe treatments to patients.  
A list  of approved companion diagnostics is published o n t h e w ebs it e o f  
the FDA (Table 1) (130). Most of these companion diagnostics target solid tumo r  
(135) for cancer therapies e.g. gastric cancer (136), lung cancer (137), and breast 
cancer (138). Several new companion diagnostic products are currently in 
different clinical trial phases for the diagnostic  a nd t r eat ment o f  r h eu mato i d 
arthritis (139), thrombotic disease (140), HIV (141,142), colorectal and prosta te 
cancers, kidney insufficiency after transplant  ( 1 43) , a n d h epa tit is  C  ( 1 44) . A  
companion diagnostic to identify the appropriate  anti-platelet  therapy 
(clopidogrel or ticagrelor) is currently in late phase of clinical trials (Clinical trial 
NCT01742117). Indeed, patients presenting a polymorphic variation of CYP2C 19 
get a low response to clopidogrel and need to be treated by ticagrelor that i s n o t 
metabolized by this cytochrome (145).  
  
                                                             
1 Thera(g)nostic comes from the combination of the words therapeutic and diagnost i c  an d 
defi nes a single dosage form containing both diagnostic and therapeutic agents (132) . It i s  
found with 2 spellings in the literature: theranostic and theragnostic.  
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Ta bl e  1 :  C ompa ni on  d ia gnosti cs a pproved by th e  FD A.  
Te st Ma n u fa cturer D ru g s In d i ca ti on 
C oba s KRAS Mu ta ti on  te st  Roch e  
C e tu x i mab 
P a n i tu mumab 
C ol ore cta l  ca nce r 
Th e ra scre en KRAS RGQ  
P C R Ki t 
Q i a ge n 
D a ko E GFR D a ko 
Th e ra scre en E GFR RGQ  
P C R Ki t 
Q i a ge n 
Afa ti n i b 
Ge fi ti n ib 
N on -sma l l  ce ll  l ung ca nce r  
P D -L1  IH C  2 2C3  D a ko P e mbrol i zumab 
C oba s E GFR Mu ta ti on Te st 
v2  
Roch e  O si me rti ni b 
C oba s E GFR Mu ta ti on Te st  Roch e  E rl oti n ib 
Ve n ta n a  ALK C D x Ve n ta n a  
C ri z oti ni b Vysi s ALK Bre a k Ap a rt 
FISH  p robe  ki t 
Abbott 
In form H e r 2 /N eu  
Ve n ta n a  
Tra stu z uma b Bre a st ca n ce r  
P a th w a y Anti  H e r-2/Ne u 
In form H e r2  D ua l ISH  D NA 
In Si te  H e r 2 /Ne u KIt  Bi oge n e x 
Sp ot –Li gh t H e r2 C ISH Ki t  
Li fe  
te ch n ol ogie s 
H e r2  C ISH  P ha rmD x Ki t  
D a ko H e r2  FISH  
H E RC E P TE ST  
Bon d  O ra cl e H e r2 IC H 
Syste m 
Le i ca  
P ATH VY SION H e r -2 D NA 
P robe  Ki t 
Abbott 
D a ko C  Ki t P h a rmD x D a ko 
Ima ti n i b 
me syl a te  
Ga stroi n te stin al stroma l  tu mors  
Ki t D 8 1 6 V Muta tion 
d e te cti on  ARUP  
La bora ori e s 
Syste mi c ma stocytosi s  
P D GFRB FISH  
Mye l od yspl astic syn drome /  
Mye l op roli ferati ve  d ise ase  
BRAC An a l ysi s C Dx Myri a d  
ge n e ti c 
O l a p a ri b O va ri a n ca n cer  
TH x ID  BRAF bi o Mé ri e u x  Tra ma te n ib 
D a bra fe ni b Me l a n oma  
BRAF V6 0 0  Roch e  Ve mu ra fe nib 
Fe rri Sca n ® 
Re son n a nce  
H e a l th  
D e fe ra siox  Th a l a ssemi a 
 
As it  can be seen in Table 1, companion diagnostics  are very often 
associated to cancer  treatments and involve biological material such as 
antibodies. However, it  is possible to deve lop companion dia gno s ti cs  f o r o t h er 
types of diseases with small molecule drug products.  The  o n ly  e xampl e t ha t i s  
approved by the FDA  is FerriScan®. I t  is a diagnostic test  based on MRI  to 
measure liver iron concentration in patients s uf f er ing  o f  β -t hala ss emi a. A s  a  
companion diagnostic of deferasirox (Exjade®) it helps physicians to identify and 
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monitor patients with non -transfusion-dependent thalassemi a f o r  a n e f f ec tiv e 
treatment (146,147).  
1.4.3 Phenotyping cocktails as companion diagnostics  
The development of companion diagnostics is gene rally based on s pe ci fi c  
genetic mutations. The capacity of patients to respond to the treatment is 
directly linked to their genotype. However, the genotype does not consider other 
factors that are not associated to the genes, s uc h a s  t he p a tie nt’ s w e ig ht a nd  
health condition, a smoking/drinking habit  or a special diet .  These 
characteristics can influence and modify the response to a drug by increa si ng  o r 
slowing down its metabolism. That is why the considerati o n o f  e n vi ro nme ntal  
factors, in addition to the genotype, is very important to define the phenotyp e o f  
the patient (148).  
Phenotyping consist  in the determination of the phenotype, by  the 
administration of an appropriate probe d r ug,  t hat i s  m eta bo li ze d b y a  g i ve n 
enzyme into a known metabolite.  I t results in the determination of the p at ien t’ s 
metabolism profile and the prediction of the drug activity. Phenotyping cocktai ls  
are a combination of several probe drugs that a re  u sed  t o  i n f i rs t  i ns tan ce  t o  
identify drug-drug interactions, leading to an induced or an inhibito r y e f f ec t o f  
one or more drugs during a combination therapy (149). Phen o typ ing  c o c k tai ls  
can be considered as companion diagnostics because they help in the eva luat io n 
of the metabolism of drugs before the implementation of a medical trea tme nt t o  
personalize it to t he patient’s needs.  
The Basel cocktail  is a phenotyping cocktail  th at w a s d ev el o ped b y  t he 
University hospital of Basel (149). Until now, there was an absence of a dedicated 
phenotyping cocktail  formulation, and thus, the 6  d if f ere nt p r ob e d rug s w e re 
administered as individual marketed medications. The diversity of dosage f o r ms 
the cocktail  can induce d ifferent release kinetics,  dosage inaccuracy and 
excipients cross-reactions (150). To overcome these issues, it was  n ec es sar y t o  
develop a single dosage form combining the p ro be  d rug s a t  t h e n ee ded d o s e, 
without inducing any physicochemical interactions. An attempt to fil l thi s g ap  i s 
described later  in the article “CombiCap, a novel drug formulation f o r  t he B as el  
phenotyping cocktail”.   
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The introduction part of this thesis reveals the importance of diagnostic 
products in helping the physicians to detect and diagnose a dis ease; allowing t h e 
adaption of medical treatments to each individual patient, based on more prec is e 
criteria than age, weight, and sex. Unfortunately, laboratories have the t en denc y  
to develop curative products for treating diseases and neglect the impo rta n ce  o f  
developing diagnostic products for accurate diagnosis to personalize medicine. In 
the following chapters, we describe the development of 2 diagnostic products, the 
first  one at the nanoparticulate level and the second one at the micropa rti cu lat e 
level.  
• PDMS-PMOXA polymersomes containing quantum dots for cellular 
imaging 
During the last decades, nanoscience was increasingly developed for  m edi c al 
purposes but mainly for drug delivery. The most common e xa mpl e i s D o x il ®,  a  
liposomal formulation encapsul ating doxorubicin for cancer chemotherapy. In the 
first  chapter, we describe the formulation of polymersomes for cellular i m agi ng . 
Polymersomes are artificial  nanovesicles made of bloc copolymers that self -
assemble into a double - layered vesicle allowing th e loading of hydrophilic 
molecules in its cavity and hydrophobic molecules in the poly mer ic  me mbra ne.  
Quantum dots are already used for medical imaging but in l im ite d a ppl ic ati o ns  
because of their toxicity. To overcome this constraining property, we d ec id e d t o  
isolate some quantum dots inside PDMS -PMOXA polymersome s a n d s tud y t he ir 
imaging properties in vitro.  
• CombiCap, a novel drug formulation for the Basel phenotyping 
cocktail 
The second chapter is based on microparticulate products for diagnostics. The 
objective of this project was to create a pharmaceutical dosage form for the Base l 
Cocktail.  The phenotyping process is important in diagnosis, for  i ns tan ce  i n t he 
evaluation of enzymes involved in the metabolism of xenobiotics, such  a s d rug s.  
Thus, with the detailed status of these enzymes, it  is p o s si ble  t o p e rs on ali z e a  
therapeutic treatment to a patient, to deliver the  r igh t d rug  a t  t he  r igh t d o se , 
avoiding any adverse effect . We developed a formulat io n p l atf o rm t ha t c a n b e 
adapted for any phenotyping cocktail  thanks to its multiple properties.  
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3.1 Nanoparticles as diagnostic product  
 
Polymersomes containing quantum dots for cellular imaging  
Marine Camblin1 , Pascal Detampel 1,  Helene Ket tig er 1 ,  D a li n W u 2 ,  V i ma lk uma r 
Balasubramanian1 , Jörg Huwyler1  
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3.2 Microparticles as diagnostic product  
 
CombiCap: A novel drug formulation for the Basel phenotyping cocktail 
Marine Camblin1 , Benjamin Berger2 , Manuel Haschke2,  Stephan Krähenbühl2,  J ö r g 
Huwyler1 , Maxim Puchkov1  
1Division of Pharmaceutical Technology, Department of Pharmaceutical Scienc es , 
University of Basel, Basel, Switzerland 
2Division of Clinical Pharmacology and Toxicology, Department o f  B i o medi ci ne,  
University of Basel, Basel, Switzerland 
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4 DISCUSSION 
  
55 
4.1 Importance of diagnosis and diagnostic products  
Diagnostic products are powerful tools that are used to reveal a  p art ic ula r 
health condition and help physicians in their diagnosis, in ord er t o  p er so n ali z e 
the treatment to the patient.  Diagnosis is often generalized and tends to 
standardize the diseases and the patients, which may lead to adverse effects t ha t 
can be fatal in some cases. Despite their added value, o nly a few diagnostic 
products are commercialized. The development of in vitro o r  i n  v i vo  d ia gno s tic  
products is left  aside at the expense of therapeuti c  pr o duc ts .  I n c h apt er 3 ,  w e 
attempted to overcome this lack with the formulati o n o f  2  t y pes  o f  d i agn o sti c  
products;  the nanoparticles for cellular imaging and the microparticles for 
phenotyping.  
The development of a diagnostic product must combine several featu res  t o  
lead to a good quality product. I t should be safe, reliable, specific,  cus to mi za ble , 
easy to formulate, and easy to use. In this c h ap ter , w e w i ll  d i sc us s h o w o u r 2  
diagnostic products fulfil l  these conditions and how they can be used in the 
objective of personalized medicine. 
4.2 Input of nanoparticles in diagnosis 
Nanodiagnostic products are mostly  used for imaging purposes. In the 
introduction, we gave an overview of nanoparticles that c a n b e u s ed e i the r f o r  
MRI , X-rays, fluorescence microscopy, SPECT, or PET. Among these nanoparticles,  
the QDs are valuable as highly fluorescent nanocrystals.  Their  optical pro per tie s 
are interesting and present many advantages such as a very low photobleaching, a 
tunable color depending on the size of the QD, and a long and bright f l uo re sc ent  
lifetime. However, the toxicity of the semiconductor core limits the use o f Q D s  i n 
cellular imaging.  
In chapter 3, we described how we formulated PDMS -PMOXA polymersomes 
to isolate the QDs from the cells to prevent any risk of toxicity. The challenge was  
to encapsulate the QDs in the core of the polyme rso me  w ith o ut a lt eri ng t h e ir  
imaging properties. The product is now safe and non-toxic as shown by the resul t  
of the MTT assay (Figure 4 in part  3.1). The stability data over weeks, months and 
even year demonstrated the cohesion of the polymer double la yer, preventing the 
escape of the QDs from the core of the polymersomes, and proving the reliab ili ty  
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of the product. The advantage of the polymersomes is their synthetic a sp ec t a nd 
the possibility to tune their membrane by diversify in g  t he  p o lym ers  a nd t he ir 
assembling process, to modify the properties of the vesic le s a nd  i mpro v e t he ir 
biocompatibility as well as their circulation time in vivo . Polymersomes a r e e as y 
to formulate and do not need long and complicated procedures to be prepar ed.  A  
simple film rehydration method followed by several extrusions to homogenize the 
size of the vesicles are the only needed steps. The loading of imaging probes is  a s 
simple because they can be added directly in the rehydration medium. Depending  
on their affinity to water , the probes can be included either inside the 
hydrophobic membrane, or in the hydrophilic core of the PDMA-PMOXA 
polymersomes.  
The polymersomes containing QDs are easy to use. A fluorescence 
microscope is sufficient for their visualization during in vi t ro  c el lul ar i ma gi ng.  
Concerning in vivo  imaging, Michalet et al. , demonstrated t hat  t he Q D s  a re s t il l  
visible through the skin of mice. The visualization of the QDs was done by 
microPET and fluorescence (151). In our case, the PDMS-PMOXA p o ly mer so mes  
were visualized by fluorescence microscopy. They could be internalized by HepG2 
cells by passive targeting and forced intake. However, to get a more precise image 
of the cells of interest, it  is possible to functionaliz e  t h e b lo c  c o po ly mer s  w i th 
several l igands and achieve a specific and active targeting (152–154).  
The vesicular structure of the polymersomes offers further opportunities i n 
the view of personalized medicine. Indeed , t he p o l yme ric  c o mp o si tio n o f  t h e 
vesicle gives the possibility to include hydrophobi c molecules within the 
membrane, as well  as hydrophilic molecules in the polymersome cavity. Thus, it  is 
possible to load a drug and an imaging probe in a single polymersome . Aliboland i 
et  al .  developed a folate receptor-target ed p o ly mer so me  c o n ta ini ng  Q D s a nd  
doxorubicin for the simultaneous imaging and treatment of breast 
adenocarcinoma. They studied the effect in vitro  and in v i vo  o n  mi ce  a nd c o u ld 
visualize the cancer cells by fluorescence microscopy . They  w ere  a ble t o  p ro v e 
the inhibitory effect of the folate on t he t umo r  b esi des  t he g o o d  t hera peu tic  
efficiency of the targeted polymersomes over the non -targeted ones and over t h e 
free doxorubicin  (155). This combination of diagnostic and therapeutic 
applications is called thera(g)nostics, and will be increasingly d eve lo pe d i n t he  
57 
future, for personalized medicine  (132). The n o v elt y o f  t h is  t o pic  h as  n o t y et  
enable the scientists to decide between the 2 spellings:  theranostics and 
theragnostics. Both words can be find in search engines.  
As mentioned in the introduction, nanoparticules can also be used as l abel s 
in immunoassays to display the result  of the test .  T h e e xa mple  o f  l at era l f l o w 
assays is interesting because they are very easy to  u se a s  t hey  j us t n ee d t o  be  
soaked with a liquid sample. The nanolabels t ha t a re  i mmo bil iz ed  o n t h e t es t 
migrate by capillarity, react with the test sample, and produce a visible s ig nal  t o  
indicate the result.  Only few drops of urine, saliva or tears are e n o ugh t o  g i ve  a  
fast  and reliable result.  The lecture of the tes t can be done without requiring a n y 
analysis equipment and thus can be performed at a point of care. Th es e t y pes  o f  
tests can be adapted for the diagnosis of various health conditions like pregnancy, 
infections, or diabetes. They can be improved with a di g i tal  l ec ture  w ind o w t o  
eliminate any doubt as to the result  of the test . They can even be co nn ec ted  t o  a  
smartphone application, allowing a better monitoring of the results in the case o f  
a disease requiring a regular follow -up (15). For no w , t he  re su lts  r emai n o n ly  
qualitative but research is done on other t y pe s o f  l a bel ing  n ano p arti c les  a nd 
other detection methods to improve LFAs to provide q ua nti tati ve  r es ults .  T h e 
characteristics of the LFAs let us imagine many w ays  t o  u se  th es e d ia gno s tic s  
products in the future. For instance, in  the detection of molecules like the 
biomarkers that are used in cancer diagnosis.  
4.3 Input of microparticulate diagnostic products  
Microparticulate diagnostic products are more well -known than 
nanodiagnostics because they are commonly used in dia gno s tic  t es ts ,  c o n tra st 
imaging, and radiopharmaceutics, to get a more accurate diagnosis. But a prec is e 
diagnosis is pointless if the patient does not respond correctly to the treatment.  
Indeed, there is a big inte r-individual variability of the different CYP 
isoforms and thus a difference in the capacity on the patients to metabolize 
certain drugs. To predict  the behavior of the patient towards a drug and 
personalize his treatment, it  is important to determine the ac tiv it y o f  h i s C Y Ps . 
This determination is called phenotyping, and is p e rf o rmed  w ith  a c o c k t ail  o f  
probe drugs that are metabolized by d ef i ned C Y Ps . E v en  t hat  ma ny r e se arc h 
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groups tried to develop their own phenotyping cocktail ,  there is a lack of 
clinically tested examples to phenotype the patients prior to the assignment  o f  a  
therapy. The Basel cocktail was developed i n  t his  i nte nti o n a t t he  U ni ve rsi ty  
hospital of Basel,  and is composed of 6 different drugs:  caffeine, efavirenz, 
flurbiprofen, metoprolol, midazolam, and omeprazole.  
Among all  phenotyping cocktails described in the literatur e, n o n e o f  t he m 
has a dedicated formulation. The CombiCap, that is presented in chapter 3, fulfills 
this gap for the Basel cocktail , with a f o r mula tio n  p lat fo r m p res ent i ng  m any  
advantages compared to the actual way of dispensing cocktails.   
The CombiCap can be considered as a diagnostic product because it i s  u sed  
to deepen the knowledge on the patient health condition by the determinati on  o f  
his phenotype. It  is a safe product because we used the minimum detectable do se  
of each drug, enabling to achieve the diagnost ic  o bj ec tiv es  w hil e l i miti ng  th e 
therapeutic effects. It  is reliable since the standardized formulation  r educ es  t he 
interaction of the excipients. The reliabili ty of the product also rests on the 
comparative in vitro  and in vivo  results that showed the equivalence of the 
CombiCap to the 6 individual marketed drugs. The stability of the product is  a ls o  
guaranteed by the multiparticulate formulation (mini-tablets )  th at p e rmit s t he  
physicochemical separation of the 6 different active ingredients. The CombiCap is 
easy to formulate because the active ingredients are simply dissolved in an 
adequate solvent and loaded in the pores of the excipient (Fujicalin®).  The critical 
step is the drying of the blend under vacuum, to evaporate the remaining solvent. 
An insufficient drying can lead to poor flowability of the blend and difficulti es  t o  
press the mini-tablets. I t is possible to customize the CombiCap for the needs of a  
phenotyping study, by specifically adapting the dosage and the composition of the 
cocktail  simply, by adding or removing some mini -tablets.  And finally,  the 
CombiCap is easy to use because it  is an oral medication. I t  improves the 
compliance of the patient with a single dosage form (compare d t o  6  i n t he  f ir st  
studies on the Basel cocktail).  The small  size of the mini -tablets give the 
possibility for children and elderly to swallow the content of the capsule in 
several intakes if they have difficulties with the hard gelatin capsule.  
Unlike the genotype that remains the same throughout life , t he  p heno t ype  
can vary depending on the living conditions. Therefore, it  would be nec ess ar y t o  
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re-determine the phenotype several t imes during the patient’s l ife. The Combi Cap 
could be given at every hospital admission, or in the case of a disease involvi ng a  
complex medical care with multiple medications leading to drug -drug 
interactions. Thus, the physician would be able to personalize a medical 
treatment by prescribing dr ugs and doses adapted to the metabolism of the 
patient,  at every stage of his l ife.  
4.4 Companion diagnostics  
Companion diagnostics are in vitro diagnostic tests that are  d ev elo pe d i n 
parallel  of the therapeutic molecule to provide essential information i n  o r der t o  
optimize the safety of a treatment and determine its applicability t o  t he  p ati ent  
(129). They are powerful tools in the domain of  d ia gno s is  a nd a r e e s sen ti all y 
based on the detection of specific mutations that are found in some cancers.  
As presented in paragraph 1.4.2,  o n ly  a  l im i ted n u mber  o f  c o mpa ni on  
diagnostics are approved by the FDA, mainly in the domain of oncology, and t he y 
rely on biomarkers as diagnostic products,  but new therapeutic areas are 
emerging. With the increasing number of drugs that specifi c all y t ar ge t c el ls  o r  
tissues, pharmaceutical companies realized that companion diagnostics can boost 
the success of their medications. Companion diagnostics can also be a grea t h elp  
in the selection of the candidates for clinical trials,  which decreases t h e c o s ts o f  
research, and achieve a faster time to market of the drug (157). In this context,  i t  
is probable that more companion diagnostics will  b e d e ve lo ped  i n t he  c o min g 
years. Table 2 shows some current facts about c o mpa nio n d i ag no st ic s a n d l et  
figure the trend for the future.  It  is o b vi o us  th at t he  n eed  o f  n ew  c o mpa nio n 
diagnostics is important and that they should be increasin gly  d ev elo p ed i n  t he 
years to come. 
Ta bl e  2 :  C urre nt fa cts a bout comp a nion d i agnostics.  Source : w w w.ge nen gne ws.com 
Diagnostic facts 
1 %  of marketed drugs have a companion diagnostic 
10 %  of marketed drugs recommend genetic testing for optimal treatment  
30 % of al l  treatments in l ate clinical development rely on biomarker data 
60 %  of al l  treatments in preclinical development rely on biomarker data  
50 %  of cl inical trials collect DNA from patients to aid in biomarker development  
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As mentioned above, the companion diagnostics are developed in 
combination with therapeutic molecules to ensure a safe and optimized treatment 
based on the information obtained on the patient’s genetic profile.  A paralle l  c a n 
be made with phenotyping cocktails, that are us ed  to  d e ter mine  t he p at ien t’ s 
metabolism regarding drugs and therefore personalize and optimize the me dic al  
treatments. In this circumstances, we can consider the phenotyping as a 
companion diagnostic test that requires  p heno t ypi ng  c o c kt ail s a s  d ia gno s tic  
products.  
Generally speaking, diagnostic products can be assimila ted  t o c o m pan io n 
diagnostics because they fit  to the description that is given in 1.4.2. Indeed , t he y 
can be used either for the screening or the identification of gene tic and 
phenotypic markers; and they can monitor the effectiveness and t he  d o si ng o f  a  
therapy.  
4.5 Personalized medicine, the future of medical practice  
Diagnosis and diagnostic products that have been discussed previo us ly  a re 
unavoidable in the instigation of perso nal iz ed  me dic i ne.  T hi s r e lat iv ely  n ew 
discipline gives the potential  to customize medical c ar e i n o r d er t o  o b tai n t he  
best response to a drug treatment, while incre as ing  t he s a f ety  o f  t he  p ati ent .  
Indeed, personalized therapy implies the specific design of a medic al  t rea tmen t 
that is compatible with the phenotype of each individual patient.   
However, it  should be noted that personalized medicine is not  i nte nde d t o  
produce unique medications for every patient. The idea i s  r at her b a sed  o n  th e 
classification of the patients suffering from a specific disease , into sub-
populations, depending on their phenotype and their predisposition to respond to 
the treatment. In the end, the objective is to opt imi ze  t he e f f ec ti ven es s o f  t h e 
treatment by adjusting the dose, and to minimize the drug tox ic it y b y s e le ct ing  
the appropriate therapeutic molecules (158).  
Personalized medicine has many advantages and is a great a d va nc e i n t he  
therapeutic field. In-depth knowledge of the patient health condition reduces  t he 
prescriptions errors and th e prescription of ineffective medications. Thus, o wi ng  
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to less drug side effects,  the adherence of the patient to the treatment is 
increased, and his life quality is improved. From a f i nan ci al p o i nt o f  v i e w, t he  
development costs of a drug can be reduced w ith the possibility to pre-selec t t he  
volunteers and the patients for the clinical trials. Personalized medicine can a ls o  
optimize the overall  cost of health care due to the individualization of the 
treatments that limits the prescription of unnecessary drugs and t he reby , t h eir  
reimbursement by health insurance.  
The research interest on personalized medicine has exponentially increased 
as shown in Figure 8. Within 30 years, the number of articles dealing with 
personalized medicine rose from 12 to over 6000 references , representing a 500 -
fold increase. Based on this results, we can predict an escalation of t h e r e sea rc h 
on the topic of personalized medicine, and consequently an increased interes t o n  
the development of diagnostic products to precise the diagnosis . The 21 st century  
brought us in a new medical era, where the trend is on personalization of 
therapies to provide the right drug, at the right dose to the right patient.  
 
Fi gu re  8 :  N umbe r of  a rti cl es re fere ncing th e p e rsonal ize d me di cine  from 1 986 to 2 0 1 6.  
Sou rce  P u bMe d. 
 
  
0
1000
2000
3000
4000
5000
6000
7000
1
98
6
1
99
0
1
99
6
2
00
0
2
00
1
2
00
2
2
00
3
2
00
4
2
00
5
2
00
6
2
00
7
2
00
8
2
00
9
2
01
0
2
01
1
2
01
2
2
01
3
2
01
4
2
01
5
2
01
6
A
rt
ic
le
s 
co
u
n
t
Years
62 
 
 
 
 
 
 
 
5 CONCLUSION AND OUTLOOK 
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Diagnosis is an ancestral  medical practice that has underg o ne a  v e ry  s h a rp 
evolution from the ancient Egypt  to the present day. Hug e a dv anc es  h av e b een  
done in this filed since the 20 th  century. Particularly, the progress in t e ch no lo gy  
and the development of diagnostic pro duc ts  b ro ugh t a n a dd iti o nal  s o urc e o f  
information to help determine the health condition of a person, and presc ribe the 
indicated medical treatment.  
Diagnostics products are used in the sampling and the analysis of body 
elements to assist  the early diagnosis of a disease or a disorder. The precis io n  o f  
the diagnosis is essential  for the personalization of the ther apies and for an 
improved medical care. Personalized medicine brings a safe and optimal t her apy  
to patients, while preventing potential  drugs side effects. I t also reduces the time  
and costs of clinical trials with the possibility to better select the  c an d id ate s.  I t  
helps to manage a disease from early detection to a response-guided medic ati o n. 
For this application, proper and accurate di ag no st ic  t o o ls  a re i n dis pen sa ble.  
However, the supply of diagnostic products is rather low and does  n o t m eet  t he 
growing demand for a more accurate diagnosis. We attempted to satisfy this  l ac k  
with the 2 diagnostic products that are presented in the chapter 3 .  
5.1  Particulate material in diagnostics 
The first  diagnostic product we described is t he PDMS-PMOXA 
polymersome. Polymersomes are very interesting  t o o ls f o r  d ia gn os is  b ec aus e 
their tunable properties and their loading capacities, make them  i dea l t o o ls  f o r 
isolating QDs or other imaging probes, from the external environment. The strong 
stability of the polymeric membrane d oes not allow the release of the 
polymersome content over weeks. Thus, the encapsulation inside the co r e o f  t h e 
vesicle limits the toxic effect of the QDs towards the cells.  
We assert that polymersomes containing QDs c a n b e u se d i n i ma gi ng f o r  
diagnostic purpose because they meet all  the previously defined requirements for 
the diagnostic products.  The physicochemical characteristics of the 
polymersomes are also interesting for thera(g)nostics. The polymerso me s c o u ld 
be used as carriers, incorporating a drug and a screening agen t , t o  m o ni to r t he  
delivery of the drug at the right site.  To achieve this goal,  2 modificat io ns  o f  t he  
PDMS-PMOXA di-bloc copolymer would be n ec es sar y.  F i rs t ,  t h e a ddi ti on  o f  a  
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linker with a targeting agent to spot the rece pto r s.  S ec o nd,  t he i n ser tio n  o f  a  
channel or a spacer is necessary to allow the d if f us io n o f  t h e d ru g t ro ug h t he 
polymeric vesicle,  because of the superior stability of the PDMS -PMOXA 
membrane.  
The second diagnostic product we formulated  is the CombiCap. This un ique  
formulation concept simplifies the phenotyping procedures. Indee d, a l l  6  p ro be  
drugs of the phenotyping cocktail  are formulated a c co rd ing  t o  a  s ta ndar diz e d 
formula, leading to identical pharmacokinetic profiles of the dru gs.  T h e d o se  o f  
each drug was care fully selected and minimized to stick to the diagnostic 
purpose, without inducing therapeutic effects. The ph eno ty pi ng d a ta o b ta ine d 
with the CombiCap were equivalent to those obtained with the indiv idua l p ro be  
drugs, proving the reliability of our formulation. The f o rmu lat io n p l atf o rm w e  
developed for the Basel cocktail  can also be applied to other phenotyping 
cocktails,  due to the versatility of the formula and of the manufacturing process of 
the CombiCap. Hence, it is possible to increase the knowledge a bout CYP a c ti vi ty  
and the metabolizer type of each person, to determine the best therapeutic option 
in case of a therapy. Other types of cocktails could also b e d ev el o ped f o r  o t he r 
metabolic enzymes like the glucuronyl -transferase that is involved in the 
metabolism of deferasirox, the companion diagnostic of FerriScan ® (159).  
The polymersomes and the CombiCap are 2 different part ic ula te p r od uc ts 
that are safe, reliable, specific,  customizable, easy to formulate a nd e a sy  t o u s e.  
We formulated them in the objective of developing new diagnostic tools, to  m ak e 
personalized medicine accessible to everyone.  
5.2 What is the future of medicine? 
The concept of “one drug fits all” ,  taking account of large patient 
populations belongs to the past. The personalized medicine represents the futu re 
and holds promise for improving health care, by enabling each patient to r ec e iv e 
earlier diagnosis, risk assessment and optimal treatment. Th e c l ea r i nc re as e o f  
the research articles involving personalized medicine confirms the importance o f  
the individualization of diagnostic procedures with the help of diagnostic 
products to achieve a better treatment of the patient.   
65 
Phenotyping cocktails and companion diagnostics deserve to be more 
considered and developed by pharmaceutical indust ri es b e ca use  t hey  p ro vi de 
essential information on the use and on the utility of drugs. They are particula rly  
useful in the case of seriou s diseases such as cancer, b ut a ls o  H IV , r heu mato i d 
arthritis,  or hepatitis C. The input they provide is huge and increases the 
knowledge about the disease and the patient.  But such diagnostic products 
remain an exception and only a few drugs have a compan ion diagnostic  p ro duc t.  
The expectation for the future is to provide a c o mpa nio n  di ag no st ic  f o r e v er y 
drug therapy. Phenotyping is as well  of a great interest because it  allows to 
anticipate the behavior of a patient regarding certain drugs, and thus, fa v o r s t he  
prescription of a medical treatment while avoiding side effects.  
In few decades, personalized diagnosis and  tr eat ment  w ill  b e a  c o mmo n  
practice in the field of medicine. The determination of the phenotype will  become  
a standard procedure integrated to every diagnosis. It  could be per fo r med u po n  
the admission of a patient at the hospital and in case of a treatme nt i n vo l vi ng a  
multi-therapy. The phenotyping could also be performed at a point of care,  u si ng 
LFAs for the detection of the metabolic ratio s. Some attempts were done to 
facilitate the analysis procedure of phenotyping with breath tests,  but no 
evidence was pointed out for the usefulness of this method (156). 
Furthermore, nanoparticles and micr op art ic les  m ig ht b e c o m bine d i n a  
single diagnosis process.  For instance;  in parallel  of writing the medical 
prescription, the doctor would add a phenotyping cockta il  d o s ag e f o r m, a s  th e 
companion diagnostic of the treatment. One hour after the ingestion of the 
cocktail , the patient uses a lateral flow assay that indicates his metabo l iz er t y pe  
within minutes. He brings this diagnostic test to the pharmacist, who will  be a ble  
to deliver the appropriate treatment bas ed on the phenotyping results.  The 
monitoring of the therapy would be then done by targeted thera(g)nostic 
nanoparticles containing an imaging probe, to c o nt ro l t he  d rug  r ele ase  t o  t he 
appropriate cellular tissue.  
 
  
66 
 
 
 
 
 
 
 
 
 
6 BIBLIOGRAPHY 
  
67 
1.  Definit ion of diagnos is . I n:  Oxfor d 
dict ionar y  [ I nt er net ] . [c it ed 2016 Jun 22] . 
Av ailable fr om: 
ht t p://w w w.oxforddictionaries.com/definit
ion/englis h/diagnos is  
2.  Summer t on N. Mak ing a diagnos is  in 
pr imar y  car e:  s y mpt oms  and cont ext . B r  J 
G en Pr act . 2004 Aug 1;54(505):570 – 1.  
3.  G UI DELI NE FOR T H E MANUFACT URE OF  I N  
V I T RO DI AG NOST I C PRODUCT S [ I nt er net ] . 
1994 [c it ed 2016 Apr  14] . Av ailable fr om: 
ht t p://fda.complianceexper t .com/agency -
document s /medical - dev ice- guidanc e/fda-
guidelines /guideline- for- the-manufact u r e -
of- in- v itr o- diagnos tic- products -1.94060 
4.  v an Middendor p JJ, Sanchez G M, B ur r idge 
AL. T he Edw in Smit h papy r us :  a c l inical  
r eappr ais al  of t he oldes t  k now n document  
on s pinal  injur ies . Eur  Spine J Off Publ Eur  
Spine Soc  Eur  Spinal  Defor m Soc Eur  Sect  
Cer v  Spine Res  Soc . 2010 Nov ;19(11):1815–
23.  
5.  Four nier  A . Diagnos ing Diabet es . J G en 
I nt er n Med. 2000 Aug;15(8):603 – 4.  
6.  B er ger  D. A  br ief his t or y  of medical  
diagnos is  and t he bir t h of t he c l inical  
labor at or y . Par t  1- - Ancient  t imes  t hr ough 
t he 19t h cent ur y . MLO Med Lab Obs . 1999 
Jul;31(7):28– 30, 32, 34– 40.  
7.  Luiggi C. T he Pee- in- a- Cup T es t , c ir ca 1500 .  
T he Scient is t  Magazine® [I nt er net ] . 2010 
Nov  [c it ed 2016 Jun 30] ;24(11). Av ailable 
fr om: ht t p://w w w .t he-
s cient is t .com/? artic les .view/ar tic leNo/29 3
45/t it le/T he- Pee- in- a- Cup- T es t - - c ir ca-
1500/ 
8.  Magior k inis  E, Diamant is  A . T he fas cinat i n g  
s t or y  of ur ine examinat ion:  Fr om ur os c op y  
t o  t he er a of micr os copy and bey ond. Di a g n  
Cy t opat hol . 2015 Dec;43(12):1020 –36.  
9.  H enr y ’s  c l inical  diagnos is  and manage m e n t  
by  labor at or y met hods  -  NLM Cat alog -  NCBI  
[ I nt er net ] . [c it ed 2016 Jun 22] . Av ailable 
fr om: 
ht t p://w w w.ncbi.nlm.nih.gov/nlmcatalog/1
01674690 
10.  T echnology  and medicine [ I nt er net ] . 
[c it ed 2016 Nov  6] . Av ailabl e fr om: 
ht t p://w w w.s ciencemuseum.org.uk/br ough
t t olife/t hemes /t echnologies 
11.  Opacic  T , Paefgen V , Lammer s  T , 
Kies s ling F . St at us  and t r ends  in t he 
dev elopment  of c l inical  diagnos t ic  agent s . 
Wiley  I nt er dis cip Rev  Nanomed 
Nanobiot echnol . :n/a- n/a.  
12.  Per s onalized Medicine Coalit ion -  
Pr ecis ion Medicine Adv ocacy  and Educat ion 
[ I nt er net ] . [c it ed 2016 Nov  6] . Av ailable 
fr om: 
ht t p://w w w.per sonalizedmedicinecoalition.
or g/ 
13.  Jain KK. Nanodiagnos t ics :  applicat ion 
of nanot echnology in molecular diagnos t ics. 
Exper t  Rev  Mol Diagn. 2003 Mar ;3(2):153 –
61.  
14.  Nune SK, G unda P, T hallapally  PK, Lin 
Y- Y, For r es t  ML, B er k land CJ. Nanopar t ic le s  
for  biomedical  imaging. Exper t  Opin Dr ug 
Deliv . 2009 Nov ;6(11):1175 – 94.  
15.  Ques ada- G onzález D, Mer k oçi A . 
Nanopar t ic le- based lat er al  flow  biosens or s.  
B ios ens  B ioelect r on. 2015 Nov  15;73:47 –
63.  
16.  Jain KK. Nanot echnology  in c l inical  
labor at or y  diagnos t ics . Clin Chim Act a. 
2005 Aug;358(1– 2):37– 54.  
17.  Key  J, Lear y  JF . Nanopar t ic les  for  
mult imodal in v iv o imaging in 
68 
nanomedicine. I nt  J Nanomedicine. 
2014;9:711– 26.  
18.  Cor mode DP, Sk ajaa T , Fay ad ZA, 
Mulder  WJM. Nanot echnology  in medical  
imaging:  pr obe des ign and applicat ions . 
Ar t er ios cler  T hr omb V as c  B iol . 2009 
Jul;29(7):992– 1000.  
19.  B aet k e SC, Lammer s  T , Kies s ling F . 
Applicat ions  of nanopar t ic les for  diagno s i s  
and t her apy  of cancer . B r  J Radiol . 2015 
Oct ;88(1054):20150207.  
20.  B er ns en MR, G uenoun J, v an T iel  ST , 
Kr es t in G P. Nanopar t ic les  and c linically  
applicable cell  t r ack ing. B r  J Radiol . 2015 
Oct ;88(1054):20150375.   
21.  Kies s ling F , Mer t ens  ME, G r imm J, 
Lammer s  T . Nanopar t ic les  for  I maging:  T o p  
or  Flop?  Radiology . 2014 Oct ;273(1):10 –28.  
22.  B as hir  MR, B hat t i  L , Mar in D, Nels on 
RC. Emer ging applicat ions  for  fer umoxy t ol  
as  a cont r as t  agent  in MRI . J Magn Res on 
I maging JMRI . 2015 Apr ;41(4):884 –98.  
23.  Scheidler  J, H euck  AF, Meier  W, Rei s e r  
MF. MRI  of pelv ic  mas s es :  efficacy  of t he 
r ect al  s uper par amagnet ic  cont r as t  agent  
Fer umoxs il . J Magn Res on I maging JMRI . 
1997 Dec;7(6):1027 – 32.  
24.  Ros en JE, Chan L, Shieh D - B , G u FX. 
I r on oxide nanopar t ic les for t arget ed cancer  
imaging and diagnos t ics . Nanomedicine 
Nanot echnol B iol  Med. 2012 Apr ;8(3):2 7 5 –
90.  
25.  H er nandez- Pedr o NY, Pineda B , 
Rangel- Lopez E, Magana- Maldonado R, 
Per ez de la Cr uz V , Sant amaia del  Angel  A , 
et  al .  Applicat ion of Nanopar t ic les  on 
Diagnos is  and T her apy  in G liomas , 
Applicat ion of Nanopar t ic les  on Diagnos is  
and T her apy  in G liomas . B ioMed Res  I nt  
B ioMed Res  I nt . 2013 Apr  18;2013, 
2013:e351031.  
26.  B or as chi P, B r accini G , G igoni R , Car t ei  
F , Per r i G . M R ent er ocly s is  us ing ir on oxi d e  
par t ic les  (fer r is t ene) as  an endoluminal  
cont r as t  agent :  an open phas e I I I  t r ial . Magn 
Res on I maging. 2004 Oct ;22(8):1085 –95.  
27.  Reimer  P, B alzer  T . Fer ucar bot r an 
(Res ov is t ):  a new  clinically  appr ov ed RES -
s pecific  cont r as t  agent  for  cont r as t -
enhanced MRI  of t he l iv er :  pr oper t ies , 
c l inical  dev elopment , and applicat ions. E u r  
Radiol . 2003 Jun;13(6):1266 – 76.  
28.  Fu T , Kong Q, Sheng H , G ao L. V alue of 
Funct ionalized Super par amagnet ic  I r on 
Oxide Nanopar t ic les  in t he Diagnos is  and 
T r eat ment  of Acut e T empor al  Lobe Epilepsy  
on MRI . Neur al  Plas t . 2016;2016:2412958.  
29.  Wan X, Song Y, Song N, Li  J, Yang L , Li  
Y, et  al . T he pr eliminar y  s t udy  of immune 
s uper par amagnet ic  ir on oxide nanopar ticles 
for  t he det ect ion of lung cancer  in ma gnet i c  
r es onance imaging. Car bohy dr  Res . 2016 
Jan;419:33– 40.  
30.  Res ch- G enger  U, G r abolle M, Cav alier e-
Jar icot  S, Nit s chk e R , Nann T . Quant um dot s  
v er s us  or ganic  dy es  as  fluor es cent  labels . 
Nat  Met hods . 2008 Sep;5(9):763 – 75.  
31.  B ilan R , Nabiev  I , Suk h anov a A. 
Quant um Dot - B as ed Nanot ools  for  
B ioimaging, Diagnos t ics , and Dr ug Deliv er y . 
Chembiochem Eur  J Chem B iol . 2016 Aug 
18;   
32.  Panagiot opoulou M, Salinas  Y, B ey azit  
S, Kunat h S, Duma L, Pr os t  E, et  al . 
Molecular ly  I mpr int ed Poly mer  Coat ed 
Quant um Dot s  for  Mult iplexed Cell  
T ar get ing and I maging. Angew  Chem I nt  Ed 
Engl . 2016 May  30;   
69 
33.  H ar dman R. A  t oxicologic  r ev iew  of 
quant um dot s :  t oxic it y  depends  on 
phy s icochemical  and env ir onmental  fact ors. 
Env ir on H ealt h Per s pect . 2006 
Feb;114(2):165– 72.  
34.  Camblin M, Det ampel P, Ket t iger  H , Wu  
D, B alas ubr amanian V , H uw y ler  J. 
Poly mer s omes  containing quant um dot s for  
cellular  imaging. I nt  J Nanomedicine. 
2014;9:2287– 98.  
35.  H ainfeld JF , Slat k in DN, Focella T M, 
Smilow it z H M. G old nanopar t ic les:  a new  X -
r ay  c ont r as t  agent . B r  J Radiol . 2006 Mar  
1;79(939):248– 53.  
36.  Kim D, Par k  S, Lee JH , Jeong YY, Jon S. 
Ant ibiofouling poly mer - coat ed gold 
nanopar t ic les  as  a cont r as t  agent  for  in v ivo 
X- r ay  comput ed t omogr aphy  imaging. J Am 
Chem Soc . 2007 Jun 20;129(24):7661 – 5.  
37.  B ot chw ay  SW, Coult er  JA , Cur r ell  FJ. 
I maging int r acellular  and s y s t emic  in v iv o 
gold nanopar t ic les  t o  enhance r adiot herapy. 
B r  J Radiol . 2015 Oct ;88(1054):20150170.  
38.  Pet er s en AL, H ans en AE, G abizon A, 
Andr es en T L. Lipos ome imaging agent s  in 
per s onalized medicine. Adv  Dr ug Deliv  Rev .  
2012 Oct ;64(13):1417– 35.  
39.  Jens en G M, B unch T H . Conv ent ional  
l ipos ome per for mance and ev aluat ion:  
les s ons  fr om t he dev elopment  of V es can. J 
Lipos ome Res . 2007;17(3 – 4):121–37.  
40.  I t o  K, H amamichi S, As ano M,  H or i Y, 
Mat s ui J, I w at a M, et  al . Radiolabeled 
l ipos ome imaging det er mines  an indicat i o n  
for  l ipos omal ant icancer  agent  in ov ar ian 
cancer  mous e xenogr aft  models . Cancer  Sc i .  
2016 Jan;107(1):60 – 7.  
41.  T anifum EA, G haghada K, V oller t  C, 
H ead E, Er ik s en JL , Annapr agada A. A  No v e l  
Lipos omal Nanopar t ic le for  t he I maging of 
Amy loid Plaque by  Magnet ic  Res onance 
I maging. J Alzheimer s  Dis  JAD. 2016 Mar  
25;52(2):731– 45.  
42.  Richar ds on V J, Jey as ingh K, Jew k es  RF ,  
Ry man B E, T at t er s all  MH . Pr oper t ies  of 
[99mT c]  t ec hnet ium- labelled l ipos omes  in 
nor mal and t umour - bear ing r at s . B iochem 
Soc T r ans . 1977;5(1):290 – 1.  
43.  Pr offit t  RT , Will iams  LE, Pr es ant  CA, 
T in G W, Uliana JA , G amble RC, et  al . T umor -
imaging pot ent ial  of l ipos omes  loaded w i t h  
I n- 111- NT A: biodis tribution in mice. J  N u c l  
Med Off Publ Soc  Nucl  Med. 1983 
Jan;24(1):45– 51.  
44.  H ender s on K, St ew ar t  J. A  dips t ick  
immunoas s ay  t o  r apidly  meas ur e s er um 
oes t r one s ulfat e concent r at ions  in hor s es . 
Repr od Fer t il  Dev . 2000;12(3 – 4):183–9.  
45.  T anak a R , Yuhi T , Nagat an i N, Endo T , 
Ker man K, T ak amur a Y, et  al . A  nov el  
enhancement  as s ay  for  
immunochr omat ogr aphic  t es t  s t r ips  us ing 
gold nanopar t ic les . Anal  B ioanal  Chem. 
2006 Aug;385(8):1414 –20.  
46.  Ahn JS, Choi S, Jang SH , Chang H J, Kim 
JH , Nahm KB , et  al . Dev elopment  of a poin t -
of- car e as s ay  s y s tem for  high - s ensit iv it y  C -
r eact iv e pr ot ein in w hole blood. Clin Chim 
Act a I nt  J Clin Chem. 2003 Jun;332(1 – 2):51–
9.  
47.  Lou SC, Pat el  C, Ching S, G or don J. One -
s t ep compet it iv e immunochr omat ogr aphic  
as s ay  for  s emiquant it at iv e det er minat ion of 
l ipopr ot ein(a) in plas ma. Clin Chem. 1993 
Apr ;39(4):619–24.  
48.  Wit t foot h S, Qin Q- P, Lund J, T ier ala I , 
Pulk k i K, T ak alo  H , et  al . 
I mmunofluor omet r ic  point - of- car e as s ay s  
for  t he det ect ion of acut e cor onar y  
70 
s y ndr ome- r elat ed noncomplexed 
pr egnancy - as s ociat ed plas ma pr ot ein A. 
Clin Chem. 2006 Sep;52(9):1794 – 801.  
49.  Abit bol  CL, Chandar  J, Onder  AM, 
Nw obi O, Mont ané B , Zil ler uelo  G . Pr ofi l i n g  
pr ot einur ia in pediat r ic  pat ient s . Pediat r  
Nephr ol  B er l  G er . 2006 Jul;21(7):995 – 1002.  
50.  Cho JH , Paek  SH . Semiquant it at iv e, ba r  
code v er s ion of immunochr omat ogr aphic  
as s ay  s y s t em for  human s er um albumin as  
model analy t e. B iot echnol B ioeng. 2001 Dec  
20;75(6):725– 32.  
51.  Choi S, Choi EY, Kim DJ, Kim JH , Kim 
T S, Oh SW. A r apid, s imple meas ur ement  of 
human albumin in w hole blood us ing a 
fluor es cence immunoas s ay  (I ). Clin Chim 
Act a I nt  J Clin Chem. 2004 Jan;339(1 –
2):147– 56.  
52.  Ang SH , T hev ar ajah T M, Woi PM, Alias  
YB , Khor  SM. A lat er al  flow  immunos ens or  
for  dir ect , s ens it iv e, and highly  s elect iv e 
det ec t ion of hemoglobin A1c in w hole 
blood. J Chr omat ogr  B  Analy t  T echnol 
B iomed Life Sci . 2016 Mar  15;1015 –
1016:157– 65.  
53.  Kik k as  I , Mallone R , Lar ger  E, V olland 
H , Mor el  N. A  r apid lat er al  flow  
immunoas s ay  for  t he det ect ion of t y r os ine 
phos phat as e- l ik e pr o t ein I A - 2 
aut oant ibodies  in human s er um. PloS One. 
2014;9(7):e103088.  
54.  Kalogianni DP, G our a S, Alet r as  AJ, 
Chr is t opoulos T K, Chanos  MG , Chr is tofi d ou  
M, et  al . Dr y  r eagent  dips t ick  t es t  combined  
w it h 23S r RNA PCR for  molecular  diagnos i s  
of bact er ial  infect ion in ar t hr oplas t y . Anal  
B iochem. 2007 Feb 15;361(2):169 – 75.  
55.  G us s enhov en G C, v an der  H oor n MA, 
G or is  MG , T er ps tr a WJ, H ar t s keer l R A ,  M o l  
B W, et  al . LEPT O dips t ick , a dips t ick  as s ay  
for  det ect ion of Lept os pir a- s pecific  
immunoglobulin M ant ibodies  in human 
s er a. J Clin Micr obiol. 1997 Jan;35(1):92 – 7.  
56.  Al- Yous if Y, Ander s on J, Char d -
B er gs t r om C, Kapil  S. Dev elopment , 
ev aluat ion, and applicat ion of lat er al - flow  
immunoas s ay  (immunochromatography) for  
det ect ion of r ot av ir us  in bov ine fecal  
s amples . Clin Diagn Lab I mmunol. 2002 
May ;9(3):723– 5.  
57.  Zhu Y, H e W, Liang Y, Xu M, Yu C, H ua 
W, et  al . Dev elopment  of a r apid, s imple 
dips t ick  dy e immunoas s ay  for  
s chis t os omias is  diagnos is . J I mmunol 
Met hods . 2002 Aug 1;266(1 – 2):1– 5.  
58.  v an Dam G J, Wicher s  JH , Fer r eir a T MF ,  
G hat i D, v an Amer ongen A, Deelder  AM. 
Diagnos is  of s chis t os omias is  by  r eagent  
s t r ip t es t  for  det ect ion of c ir culat ing 
cat hodic  ant igen. J Clin Micr obiol . 2004 
Dec;42(12):5458– 61.  
59.  Zhang G - P, G uo J- Q, Wang X- N, Yang J-
X, Yang Y- Y, L i  Q- M, et  al . Dev elopment  and 
ev aluat ion of an immunochr omat ogr aphic  
s t r ip for  t r ichinellos is  det ect ion. V et  
Par as it ol . 2006 Apr  30;137(3 – 4):286–93.  
60.  Ok u Y, Kamiy a K, Kamiy a H , Shibahar a 
Y, I i  T , Ues ak a Y. Dev elopment  of 
o ligonucleot ide lat er al - flow  immunoas s ay  
for  mult i - par amet er  det ect ion. J I mmunol 
Met hods . 2001 Dec 1;258(1 – 2):73–84.  
61.  Car t er  DJ, Car y  RB . Lat er al  flow  
micr oar r ay s :  a nov el  plat for m for  r apid 
nucleic  acid det ect ion bas ed on 
miniat ur ized lat er al  flow  chr omat ogr a p h y .  
Nucleic  Acids  R es . 2007 May ;35(10):e74.  
62.  Clav ijo  E, Díaz R , Anguit a A , G ar cía A , 
Pinedo A, Smit s  H L. Compar is on of a 
dips t ick  as s ay  for  det ect ion of B r ucella -
s pecific  immunoglobulin M ant ibodies  w i t h  
71 
ot her  t es t s  for  s er odiagnos is  of human 
br ucellos is . Clin Diagn Lab  I mmunol. 2003 
Jul;10(4):612– 5.  
63.  H o J- AA, Wauchope RD. A  St r ip 
Lipos ome I mmunoas s ay  for  Aflat oxin B 1. 
Anal  Chem. 2002 Apr  1;74(7):1493 – 6.  
64.  T ang D, Sauceda JC, Lin Z , Ot t  S, B as ova 
E, G or y achev a I , et  al . Magnet ic  nanogold 
micr os pher es - bas ed lat er al- flow  
immunodips t ick  for  r apid det ect ion of 
aflat oxin B 2 in food. B ios ens  B ioelect r on. 
2009 Oct  15;25(2):514 – 8.  
65.  Zhang C, Zhang Y, Wang S. 
Dev elopment  of mult ianaly t e flow -t h r o ug h  
and lat er al - flow as s ays us ing gold par t ic l e s  
and hor s er adis h per oxidas e as  t r acer s  for  
t he r apid det er minat ion of car bar y l  and 
endos ulfan in agr icult ur al  pr oduct s. J Ag r i c  
Food Chem. 2006 Apr  5;54(7):2502 – 7.  
66.  Wang S, Quan Y, Lee N, Kennedy  I R . 
Rapid det er minat ion of fumonis in B 1 in 
food s amples  by  enzy me- link ed 
immunos or bent  as s ay  and colloidal  gold 
immunoas s ay . J Agr ic  Food Chem. 2006 A p r  
5;54(7):2491– 5.  
67.  V er heijen R , St out en P, Cazemier  G , 
H aas noot  W. Dev elopment  of a one s t ep 
s t r ip t es t  for  t he det ect ion of s ulfadimidin e  
r es idues . T he Analy s t . 1998 
Dec;123(12):2437– 41.  
68.  Aldus  CF, V an Amer ongen A, Ar iëns  
RMC, Peck  MW, Wicher s  JH , Wy at t  G M. 
Pr inciples  of s ome nov el  r apid dips t ick  
met hods  for  det ect ion and char act er izat io n  
of v er ot oxigenic  Es cher ichia coli . J Appl 
Micr obiol . 2003;95(2):380– 9.  
69.  Car r io  A , Sampedr o C, Sanchez - Lopez 
JL , Pimient a M, Campoy  P. Aut omat ed Low -
Cos t  Smar t phone- B ased Lat er al  Flow Saliv a  
T es t  Reader  for  Dr ugs - of- Abus e Det ect ion. 
Sens or s . 2015;15(11):29569 –93.  
70.  B ow en RAR, G eor ge DT , H or t in G L. 
Fals e- negat iv e r es ult  for  cocaine 
met abolit es  on a lat er al - flow  dr ug t es t  s l ide 
cor r ect ed by  dilut ion. Clin Chem. 2005 
Apr ;51(4):790–1.  
71.  Pappas  MG , Schant z PM, Cannon LT , 
Wahlquis t  SP. Dot - ELI SA for  t he r apid 
s er odiagnos is  of human hy dat id dis eas e. 
Diagn I mmunol. 1986;4(6):271 –6.  
72.  Mar k  D, H aeber le S, Rot h G , St et t en F 
v on, Zenger le R . Micr ofluidic lab - on-a- ch i p  
plat for ms :  r equir ement s , char act er is t ics  
and applicat ions . Chem Soc Rev . 2010 Feb 
24;39(3):1153– 82.  
73.  Salieb- B eugelaar  G B , H unzik er  PR. 
T ow ar ds  nano - diagnos t ics  for  r apid 
diagnos is  of infect ious  dis eas es  –  cur r ent  
t echnological  s t at e. Eur  J Nanomedicine. 
2014;6(1):11– 28.  
74.  Wang Y, Xu H , Wei M, G u H , Xu Q, Zhu 
W. St udy  of s uper par amagnet ic  
nanopar t ic les  as  labels  in t he quant it at iv e 
lat er al  flow  immunoas s ay . Mat er  Sci Eng  C. 
2009 Apr  30;29(3):714 – 8.  
75.  Pos t huma- T r umpie G A, Kor f J, v an 
Amer ongen A. Lat er al  flow  (immuno)as s ay :  
it s  s t r engt hs , w eak nes s es , oppor t unit ies  
and t hr eat s . A  l it er at ur e s ur v ey . Anal  
B ioanal  Chem. 2009 Jan;393(2):569 – 82.  
76.  T ang D, Cui Y, Chen G . Nanopar t ic le-
bas ed immunoas s ay s  in t he biomedical  
field. Analy s t . 2013 Jan 22;138(4):981 – 90.  
77.  Junt unen E, My y r y läinen T , Salminen 
T , Souk k a T , Pet t er s s on K. Per for mance of 
fluor es cent  eur opium(I II) nanopar tic les  and 
colloidal  gold r epor t er s  in lat er al  flow  
72 
bioaffinit y  as s ay . Anal  B iochem. 2012 Sep 
1;428(1):31– 8.  
78.  H ui W, Zhang S, Zhang C, Wan Y, Zhu J, 
Zhao G , et  al . A  nov el  lat er al  flow  as s ay  
bas ed on G oldMag nanopar t ic les  and it s  
c l inical  applicat ions  for  genot y ping of 
MT H FR C677T  poly mor phis ms . Nanos cale. 
2016 Feb 14;8(6):3579 – 87.  
79.  Nur ul  Najian AB , Engk u Nur  Sy afir a h  E  
a. R , I s mail  N, Mohamed M, Yean CY. 
Dev elopment  of mult iplex loop mediat ed 
is ot her mal amplificat ion (m - LAMP) label -
bas ed gold nanopar t ic les  lat er al  flow  
dips t ick  bios ens or  for  det ect ion of 
pat hogenic  Lept os pir a. Anal  Chim Act a. 
2016 Jan 15;903:142 – 8.  
80.  H w ang J, Lee S, Choo J. Applicat ion of a  
SERS- bas ed lat er al  flow  immunoas s ay  s t ri p  
for  t he r apid and s ens it iv e det ect ion of 
s t aphy lococcal  ent er ot oxin B . Nanos cale. 
2016 Jun 2;8(22):11418– 25.  
81.  T oubanak i DK, At hanas iou E, 
Kar agouni E. G old nanopar t ic le- bas ed 
lat er al  flow  bios ens or  for  r apid v is ual  
det ect ion of Leis hmania- s pecific  DNA 
amplificat ion pr oduct s . J Micr obiol  
Met hods . 2016 May  30;127:51 – 8.  
82.  G r eenw ald R , Es fandiar i J, Les ell ier  S, 
H ought on R, Pollock  J, Aagaar d C, et  al . 
I mpr ov ed s er odetection of My cobact e r i u m  
bov is  infect ion in badger s  (Meles  meles ) 
us ing mult iant igen t es t  for mat s . Diagn 
Micr obiol  I nfect  Dis . 2003 Jul;46(3):197 –
203.  
83.  Noguer a P, Pos t huma- Tr umpie G A, v an  
T uil  M, v an der  Wal FJ, de B oer  A , Moer s  
APH A, et  al . Car bon nanopar t ic les  in lat er a l  
flow  met hods  t o  det ect  genes  encoding 
v ir ulence fact or s  of Shiga t oxin - pr oducing 
Es cher ichia coli . Anal  B ioanal  Chem. 2011 
Jan;399(2):831– 8.  
84.  Pos t huma- T r umpie G A, Wicher s  JH , 
Koet s  M, B er ends en LB JM, v an Amer ongen 
A. Amor phous  car bon nanopar t ic les :  a 
v er s at ile label  for  r apid diagnos t ic  
(immuno)as s ay s . Anal  B ioanal  Chem. 2012 
Jan;402(2):593– 600.  
85.  V annoy  CH , T av ar es  AJ, Noor  MO, 
Udday as ank ar  U, Kr u ll  UJ. B ios ens ing w it h 
Quant um Dot s :  A  Micr ofluidic  Appr oach. 
Sens or s . 2011 Oct  18;11(10):9732 –63.  
86.  G oldman ER, Clapp AR, Ander s on G P, 
Uy eda H T , Maur o JM, Medint z I L , et  al . 
Mult iplexed T oxin Analy s is  Us ing Four  
Color s  of Quant um Dot  Fluor or eagent s. A nal  
Chem. 2004 Feb 1;76(3):684 – 8.  
87.  Edw ar ds  KA, B aeumner  AJ. Lipos ome -
enhanced lat er al - flow  as s ay s  for  t he 
s andw ich- hy br idizat ion det ect ion of RNA. 
Met hods  Mol B iol  Clift on NJ. 2009;504:185 –
215.  
88.  Wen H - W, B or ejs za- Wy s ock i W, 
DeCor y  T R, Dur s t  RA. Dev elopment  of a 
compet it iv e l ipos ome- bas ed lat er al  flow  
as s ay  for  t he r apid det ect ion of t he 
aller genic  peanut  pr ot ein Ar a h1. Anal  
B ioanal  Chem. 2005 Jul;382(5):1217 – 26.  
89.  Edw ar ds  KA, B aeumner  AJ. 
Opt imizat ion of DNA - t agged dy e-
encaps ulat ing l ipos omes  for  lat er al - flow  
as s ay s  bas ed on s andw ich hy br idizat ion. 
Anal  B ioanal  Chem. 2006 Nov ;386(5):1335–
43.  
90.  Mak  WC, Sin KK, Chan CPY, Wong LW, 
Renneber g R . B iofunct ionalized indigo -
nanopar t ic les  as  biolabels  for  t he 
gener at ion of pr ecipit at ed v is ible s igna l  in 
immunodips t ick s . B ios ens  B ioelect r on. 
2011 Mar  15;26(7):3148 – 53.  
73 
91.  Par k  J- M, Jung H - W, Chang YW, Kim H -
S, Kang M- J, Py un J- C. Chemilumines cence 
lat er al  flow  immunoas s ay  bas ed on Pt  
nanopar t ic le w it h per oxidas e act ivit y. A n a l  
Chim Act a. 2015 Jan 1; 853:360– 7.  
92.  Par olo  C, Medina- Sánchez M, Es cos ur a-
Muñiz A de la, Mer k oçi A . Simple paper  
ar chit ect ure modificat ions lead t o  enhanced 
s ens it iv it y  in nanopar t ic le bas ed lat er al  
flow  immunoas s ay s . Lab Chip. 2013 Jan 
2;13(3):386– 90.  
93.  Xu H , Chen J, B ir r enk ot t  J, Zhao JX, 
T ak alk ar  S, B ar y eh K, et  al . G old -
nanopar t ic le- decorat ed s il ica nanor ods  f o r  
s ens it iv e v is ual  det ection of pr oteins .  A n a l  
Chem. 2014 Aug 5;86(15):7351 – 9.  
94.  G e C, Yu L , Fang Z, Zeng L . An enhanced 
s t r ip bios ens or  for  r apid and s ens it iv e 
det ect ion of his t one met hy lat ion. Anal  
Chem. 2013 Oct  1;85(19):9343 –9.  
95.  Zhu X, Shah P, St off S, Liu H , Li  C. A  
paper  elect r ode int egr at ed lat er al  flow  
immunos ens or  for  quant it at iv e analy s is  of 
oxidat iv e s t r es s  induced DNA damage. T he 
Analy s t . 2014 Jun 7;139(11):2850 – 7.  
96.  Ak anda MR, Joung H - A, T amilav an V , 
Par k  S, Kim S, H y un MH , et  al . An 
int er fer ence- free and r apid elect r ochemical  
lat er al - flow  immunoas s ay  for  one- s t ep 
ult r as ens it iv e det ect ion w it h s er um. T he 
Analy s t . 2014 Mar  21;139(6):1420 –5.  
97.  Liu C, Jia Q, Yang C, Qiao R , Jing L , 
Wang L, et  al . Lat er al  flow  
immunochr omat ogr aphic as s ay  for  s ensitive 
pes t ic ide det ect ion by  us ing Fe3O4 
nanopar t ic le aggr egat es  as  color  r eagent s . 
Anal  Chem. 2011 Sep 1;83(17):6778 – 84.  
98.  Li  M, Yang H , Li  S,  Zhao K, Li  J, Jiang D, 
et  al . Ult r as ens it iv e and quant it at iv e 
det ect ion of a new  β - agonis t  
pheny let hanolamine A by  a nov el  
immunochr omat ogr aphic  as s ay  bas ed on 
s ur face- enhanced Raman s cat t er ing (SERS) .  
J Agr ic  Food Chem. 2014 Nov  
12;62(45):10896– 902.  
99.  Qin Z , Chan WCW, B oulw ar e DR, Ak k i n  
T , B ut ler  EK, B is chof JC. Significant ly  
impr ov ed analy t ical  s ens it iv it y  of lat er al  
flow  immunoas s ay s  by  us ing t her mal 
cont r as t . Angew  Chem I nt  Ed Engl . 2012 Apr  
27;51(18):4358– 61.  
100.  G uidelines  for  AT C c las s ificat i on and 
DDD as s ignement  [ I nt er net ] . 2016 [c it ed 
2016 Jun 24] . Av ailable fr om: 
ht t p://w w w.w hocc.no/atc_ddd_publications
/guidelines / 
101.  Foegeding NJ, Cas t on RR, McClain MS, 
Ohi MD, Cov er  T L. An Ov er v iew  of 
H elicobact er  py lor i V acA T oxin B iology . 
T oxins . 2016;8(6).  
102.  H elik it  -  Ur ea B r eat h T es t  [ I nt er net ] . 
[c it ed 2016 May  13] . Av ailable fr om: 
ht t p://w w w .helik it .com/en/helik it - ur ea-
br eat h- t es t/ 
103.  Py lobact ell  EMEA r epor t  [ I nt er net ] . 
[c it ed 2016 May  18] . Av ailable fr om: 
ht t p://w w w.ema.eur opa.eu/docs /en_ GB /do
cument _libr ar y /EPAR_ -
_Summar y _for _the_public/human/00015 1 /
WC500045751.pdf 
104.  Par k  SJ, Par k  YH , Lee SI , Lee DC, Yong 
D, Kim JH . Compar is on B et w een a New  L o w  
Dos e Ur ea Caps ule T es t  and t he 
Conv ent ional  UB iT (R) T ablet  T es t  for  t he 
Det ect ion of H elicob act er  py lor i I nfect ion. 
Kor ean J Lab Med. 2006 Apr ;26(2):81 –5.  
105.  H elicobact er  py lor i Ur ea B r eat h T es t , 
I nfr a- r ed (UB iT ) [ I nt ernet ]. [c it ed 2016 May  
13] . Av ailable fr om: 
74 
ht t p://w w w.ques tdiagnos tics.com/t est cent
er /t es t guide.act ion?dc=TS_Hpy lori_UBiT  
106.  PT . Ot s uk a I ndones ia [ I nt ernet ]. [c it ed  
2016 Oct  23] . Av ailable fr om: 
ht t p://w w w.ots uka.co.id/en/product /detail
/53/40//y es  
107.  Mock  T , Yat s coff R , Fos t er  R , H y u n  J H ,  
Chung I S, Shim CS, et  al . Clinical  v alidat ion 
of t he H elik it :  a 13C ur ea br eat h t es t  us ed 
for  t he diagnos is  of H elicobact er  py lor i 
infect ion. Clin B iochem. 1999 Feb;32(1):59–
63.  
108.  H elik it  -  Pat ient  I nfor mat ion 
[ I nt er net ] . [c it ed 2016 May  13] . Av ailable 
fr om: 
ht t p://w w w .helik it .com/fr /infor mat ion -
pour - pat ient s/ 
109.  G is ber t  JP, G omollón F, Domínguez -
Muñoz JE, B or da F , Jiménez I , V ázquez MA, 
et  al . [Compar is on bet w een t w o 13C - ur ea 
br eat h t es t s  for  t he diagnos is  of 
H elicobact er py lori infect ion:  is otope r a t io  
mas s  s pect r omet er  v er s us  infr ar ed 
s pect r omet er] . G as tr oent erol H epat ol . 2003 
Mar ;26(3):141– 6.  
110.  Ar idol  H omepage [ I nt er net ] . Ar idol . 
[c it ed 2016 May  13] . Av ailable fr om: 
ht t p://w w w.ar idol .info/ 
111.  Phar maxis . Ar idol® [I nt er net ] . 
Phar maxis . [c it ed 2016 May  13] . Av ailable 
fr om: 
ht t p://w w w .phar maxis .com.au/appr ov e d-
pr oduct s /aridol/ 
112.  B ar ben J, St r ippoli  M - PF, T r achs el  D, 
Schil ler  B , H ammer  J, Kuehni CE. Effect  of 
mannit ol  dr y  pow der  challenge on exhaled 
nit r ic  oxide in childr en. PloS One. 
2013;8(1):e54521.  
113.  B ar ben J, Kuehni CE, St r ippoli  M - PF, 
Schil ler  B ,  H ammer  J, T r achs el  D, et  al . 
Mannit ol  dr y  pow der  challenge in 
compar is on w it h exer cis e t es t ing in 
childr en. Pediat r  Pulmonol. 2011 
Sep;46(9):842– 8.  
114.  B r annan JD, Por s bjer g C, Ander s on S D .  
I nhaled mannit ol  as  a t es t  for  br onchial  
hy per - r es pons iv enes s .  Exper t  Rev  Res pir  
Med. 2009 Oct ;3(5):457 – 68.  
115.  Ander s on SD. Met hod and dev ice for  
t he pr ov ocat ion of air  pas s age nar r ow ing 
and/or  t he induct ion of s ept um. [ I nt er ne t ] .  
1996 [c it ed 2016 May  13] . Av ailable fr om: 
ht t ps ://docs.google.com/viewer ?url=patent
images .s t or age.googleapis.com/pdfs /US581
7028.pdf 
116.  Os mohale ® [I nt er net ] . Ar idol . [c it ed 
2016 Oct  23] . Av ailable fr om: 
ht t p://w w w.ar idol .info/united -k ingdom 
117.  WH OCC -  AT C/DDD I ndex [ I nt er net ] . 
[c it ed 2016 Jun 27] . Av ailable fr om: 
ht t p://w w w.w hocc.n o/atc_ddd_index/?code
=V 08& s how des cript ion=yes  
118.  Not ice pat ient  -  MI CROPAQUE, 
s us pens ion buv able ou r ect ale -  B as e de 
données  publique des  médicament s  
[ I nt er net ] . [c it ed 2016 Jun 27] . Av ailable 
fr om: ht t p://bas e- donnees -
publique.medicament s .gouv .fr/affi chageDoc
.php? s pecid=61522753& typedoc=N 
119.  Not ice pat ient  -  LUMI REM 175 mg/l , 
s us pens ion buv able et  r ect ale -  B as e de 
données  publique des  médicament s  
[ I nt er net ] . [c it ed 2016 Jun 24] . Av ailable 
fr om: ht t p://bas e- donnees -
publique.medicament s .gouv .fr/affic hageDoc
.php? s pecid=60581542& typedoc=N 
120.  Qin S, Cas k ey  CF, Fer r ar a KW. 
Ult r as ound cont r as t  micr obubbles  in 
75 
imaging and t her apy :  phy s ical  pr inciples  
and engineer ing. Phy s  Med B iol . 2009 Mar  
21;54(6):R27.  
121.  Nanda NC, Schlief R , G oldber g B B . 
Adv ances  in Echo I maging Us ing Cont r as t  
Enhancement . Spr inger  Science &  B us ines s  
Media;  2012. 688 p.  
122.  T amás i F , Weidner  A , Domok os  N, 
B edr os  RJ, B agdány  S. ECH OV I ST - 200 
enhanced hy s t er o - s onogr aphy :  A  new  
t echnique in t he as s es s ment  of infer t il it y . 
Eur  J Obs t et  G y necol  Repr od B iol . 2005 Au g  
1;121(2):186– 90.  
123.  Radiophar maceut icals  [ I nt er net ] . 
[c it ed 2016 May  18] . Av ailable fr om: 
ht t p://w w w.w ho.int/medicines /publicat ion
s /phar macopoeia/Radgenmono.pdf  
124.  What  is  nuclear  medicine ?  [ I nt ern e t ] .  
[c it ed 2016 May  18] . Av ailable fr om: 
ht t p://int er active.s nm.org/docs/w hat isnuc
med2.pdf 
125.  Schil l ing t es t :  MedlinePlus  Medical  
Ency clopedia [ I nt er net ] . [c it ed 2016 Jun 
27] . Av ailable fr om: 
ht t ps ://w w w.nlm.nih.gov/medlineplus/enc
y /ar t ic le/003572.ht m 
126.  V it amin B 12 Defic iency  -  Amer ican 
Family  Phy s ic ian [ I nt ernet] . [c ited 2016 Jun  
27] . Av ailable fr om: 
ht t p://w w w.aafp.org/afp/2003/0301/p979
.ht ml  
127.  P S S, PROMI LA M. H uman B ody  
Meas ur ement s :  Concept s And Applicat ion s . 
PH I  Lear ning Pv t . Lt d.;  2009. 265 p.  
128.  Kongk aew  C, Noy ce PR, As hcr oft  DM. 
H os pit al  admis s ions  as s ociat ed w it h 
adv er s e dr ug r eact ions : a s y s temat ic r ev iew 
of pr os pect iv e obs er v at ional  s t udies . Ann 
Phar macot her . 2008 Jul;42(7):1017 – 25.  
129.  Jør gens en JT . Companion diagnos t ics :  
t he k ey  t o  per s onalized medicine. 
For ew or d. Exper t  Rev  Mol Diagn. 2015 
Feb;15(2):153– 6.  
130.  H ealt h C for  D and R. I n V it r o  
Diagnos t ics  -  Companion Diagnos t ics  
[ I nt er net ] . [c it ed 2016 Jul  31] . Av ailable 
fr om: 
ht t p://w w w.fda.gov/MedicalDev ice s /Produ
ct s andMedicalPr ocedures/I nVitr oDiagnost i
cs /ucm407297.ht m 
131.  Shar ma A, Zhang G , As lam S, Yu K, Chee 
M, Palma JF . Nov el  Appr oach for  Clinical  
V alidat ion of t he cobas  KRAS Mut at ion T es t  
in Adv anced Color ect al  Cancer . Mol Diagn 
T her . 2016 Mar  16;   
132.  Pene F , Cour t ine E, Car iou A, Mir a J - P. 
T ow ar d t her agnos tics . Cr it Car e Med .  2 0 0 9  
Jan;37(1 Suppl):S50 - 58.  
133.  Agar w al A , Res s ler  D, Sny der  G . T he 
cur r ent  and fut ur e s t at e of companion 
diagnos t ics . Phar macogenomics  Per s  Med. 
2015 Mar  31;8:99 – 110.  
134.  V er gar a- Lluri ME, Moat amed NA, H o n g  
E, Apple SK. H igh concor dance bet w een 
H er cepT es t  immunohis t ochemis t r y  and 
ERB B 2 fluor es cence in s it u hy br idizat ion 
befor e and aft er  implement at ion of 
Amer ican Societ y  of Clinical  
Oncology /College of Amer ican Pat holog y  
2007 guidelines . Mod Pat hol . 2012 
Oct ;25(10):1326–32.  
135.  Wat anabe A. [Companion Diagnos t ics  
for  Solid T umor s ] . Rins ho B y or i. 2015 
Nov ;63(11):1310–5.  
136.  Yoo C, Par k  YS. Companion diagnos t ics  
for  t he t ar get ed t her apy  of gas t r ic  cancer . 
Wor ld J G as t r oent er ol . 2015 Oct  
21;21(39):10948– 55.  
76 
137.  Conde E, H er nandez S, Pr iet o  M, 
Mar t inez R , Lopez - Rios  F . Pr ofile of V ent ana 
ALK (D5F3) companion diagnos t ic  as s ay  for  
non- s mall- cell  lung car cinomas. Exper t  R e v  
Mol Diagn. 2016 Jun;16(6):707 – 13.  
138.  T amur a G , Os ak abe M, Yanagaw a N, 
Ogat a S, Nomur a T , Fuk us hima N, et  al . 
Compar is on of H ER2 immunohis t ochemica l  
r es ult s  us ing a monoclonal  ant ibody  (SV 2 -
61γ ) and a poly clonal  ant ibody  (for  Dak o 
H er cepT es t ) in adv anced gas t r ic  cancer . 
Pat hol  I nt . 2012 Aug;62(8):51 3– 7.  
139.  Kumagai S. [Opt imal T r eat ment  for  
Rheumat oid Ar t hr it is  w it h Companion 
Diagnos t ics ] . Rins ho B y or i. 2015 
Nov ;63(11):1328 –35.  
140.  Mas uda Y, Mat s uno K, Shimizu C. 
[Companion Diagnos t ics  for  T hr ombot ic  
Dis eas e] . Rins ho B y or i. 2015 
Nov ;63(11):1316 –22.  
141.  Fuk ut ak e K. [Companion Diagnos t ics  
for  Select ing Ant ir et r ov ir al  Dr ugs  agains t  
H I V - 1] . Rins ho B y or i. 2015 
Nov ;63(11):1323 –7.  
142.  V alent i  WM. Companion diagnos t ic  
t es t s  in H I V  medicine:  t he r oad t o  
per s onalized medicine. AI DS Read. 2007 
Nov ;17(11):546–9.  
143.  Roche companion diagnos t ics  
[ I nt er net ] . [c it ed 2016 Jun 30] . Av ailable 
fr om: ht t p://r oche.ns p -
r epor t s .ch/10/ar /diagnos tics_en/roch e _ c o
mpanion_diagnos t ics.htm  
144.  Colucci G . Molecular  diagnos t ic  and 
pr edict iv e t es t s in t he ev olut ion of ch r o n ic  
hepat it is  C ant i - v ir al  t herapies . B MC I n f e c t  
Dis . 2012 Nov  12;12(Suppl 2):S8.  
145.  Zhang L, Cui G , Li  Z , Wang H , Ding H , 
Wang DW. Compar is on of H igh - Res olut ion 
Melt ing Analy s is , T aqMan  Allelic  
Dis cr iminat ion As s ay , and Sanger  
Sequencing for  Clopidogr el  Efficacy  
G enot y ping in Rout ine Molecular  
Diagnos t ics . J Mol Diagn. 2013 
Sep;15(5):600– 6.  
146.  Sav ani B N. Fer r it in and Fer r iScan in 
H CT  r ecipient s . B lood. 2013 Aug 
29;122(9):1539– 41.  
147.  Meer pohl JJ, Ant es  G , Rück er  G , 
Fleeman N, Mot s chall  E, Ni emey er  CM, et  a l .  
Defer as ir ox for  managing ir on ov er load in 
people w it h t halas s aemia. Cochr ane 
Dat abas e Sy s t  Rev . 2012 Feb 
15;(2):CD007476.  
148.  Phenot y pe. I n [c it ed 2016 Jul  30] . 
Av ailable fr om: 
ht t p://w w w.oxforddictionaries.com/definit
ion/englis h/pheno t y pe 
149.  Donzell i  M, Der ungs  A, Ser r at or e M - G , 
Noppen C, Nezic  L , Kr ähenbühl S, et  al . T he 
bas el  cock t ail  for  s imult aneous  phenot yping 
of human cy t ochr ome P450 is ofor ms  in 
plas ma, s aliv a and dr ied blood s pot s . Clin 
Phar macok inet . 2014 Mar ;53(3):271 –82.  
150.  Camblin M, B er ger  B , H as chk e M, 
Kr ähenbühl S, H uw y ler  J, Puchk ov  M. 
CombiCap:  A  nov el  dr ug for mulat ion for  t he  
bas el  phenot y ping cock t ail . I nt  J Phar m. 
2016 Ok t ober ;512(1):253 –61.  
151.  Michalet  X, Pinaud FF, B ent olila LA, 
T s ay  JM, Doos e S, Li  JJ, et  al . Quant um Dot s  
for  Liv e Cells , in V iv o I maging, and 
Diagnos t ics . Science. 2005 Jan 
28;307(5709):538 – 44.  
152.  B ak alov a R , Lazar ov a D, Nik olov a B , 
At anas ov a S, Zlat ev a G , Zhelev  Z , et  al . 
Deliv er y  of s ize- contr olled long-circulat in g  
poly mer s omes in s ol id t umour s, v is uali z e d  
by  quant um dot s  and opt ical  imaging in 
77 
v iv o. B iot echnol B iotechnol Equip. 2015 Ja n  
2;29(1):175– 80.  
153.  B ak alov a R , Zhelev  Z , Nik olov a B , 
Mur ay ama S, Lazar ov a D, T s onev a I , et  al . 
Ly mph node mapping us ing quant um dot -
labeled poly mer s omes . G en Phy s iol  
B iophy s . 2015 Oct ;34(4):393 –8.  
154.  Cant on I , B at t aglia G . Poly mer s omes -
mediat ed deliv er y  of fluor es cent  pr obes  for  
t ar get ed and long- t er m imaging in l iv e cell  
micr os copy . Met hods  Mol B iol  Clift on NJ. 
2013;991:343– 51.  
155.  Alibolandi M, Abnous  K, Sadeghi F , 
H os s eink hani H , Ramezani M, H adizadeh F. 
Folat e r ecept or - t ar get ed mult imodal 
poly mer s omes for deliver y of quant um dot s  
and doxor ubicin t o  br eas t adenocarcinoma:  
I n v it r o  and in v iv o ev aluat ion. I nt  J Pha r m .  
2016 Mar  16;500(1 – 2):162–78.  
156.  Opdam FL, Modak  AS, G elder blom H , 
G uchelaar  H - J. B r eat h t es t s  t o  phenot y pe 
dr ug dis pos it ion in oncology . Clin 
Phar macok inet . 2013 Nov ;52(11):919 –26.  
157.  V ogenber g FR, B ar as h CI , Pur s el  M. 
Per s onalized Medicine. Phar m T her . 2010 
Nov ;35(11):624–42.  
158.  Annadur ai K, Danas ek ar an R , Mani G . 
Per s onalized medicine:  A  par adigm s hift  
t ow ar ds  pr omis ing healt h car e. J Phar m 
B ioall ied Sci . 2016;8(1):77 – 8.  
159.  Miner s  JO, Mack enzie PI , Knight s  KM. 
T he pr edict ion of dr ug- glucur onidat ion 
par amet er s  in  humans :  UDP-
glucur onos y lt r ans fer as e enzy me - s elect iv e 
s ubs t r at e and inhibit or pr obes for  r eact i on  
phenot y ping and in v it r o – in v iv o 
ext r apolat ion of dr ug c lear ance and dr ug -
dr ug int er act ion pot ent ial . Dr ug Met ab Rev .  
2010 Feb 1;42(1):196 – 208.  
78 
 
 
 
 
 
 
 
7  APPENDIX 
 
  
79 
 
7.1 Use of nanoparticles in therapeutics 
 
Nanomaterials: Applications in Therapeutics  
Dominik Witzigmann, Marine Camblin, Jörg Huwyler, Vimalkumal 
Balasubramanian 
Division of Pharmaceutical Technology, University of Basel, Basel,  Switzerland  
 
Encyclopedia of  Biomedical Polymers and Polymer Biomaterials, 2015, 
Taylor & Francis 
  
80 
 
  
81 
 
  
82 
 
  
83 
 
  
84 
 
  
85 
 
  
86 
 
  
87 
  
88 
  
89 
 
  
90 
 
  
91 
 
  
92 
  
93 
 
